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 Electrospinning has the capacity to create fibers of 
natural or synthetic polymers with dimensions that are 
similar to analogous fibers in native tissue.   Mats 
consisting of fibers of these sub-micron dimensions have 
shown promise in provoking little immune response and in 
offering a habitable environment for cell proliferation.  
Fibrinogen is a natural protein capable of being 
xv 
 
electrospun and offers the benefit of existing as part of 
the natural coagulation cascade.  Mats of fibrinogen could 
be utilized as possible hemostatic dressings or as an early 
scaffold for cell migration for either wound repair or 
tissue engineering.  The addition of antibiotic into such a 
dressing/scaffold could prevent infection during 
healing/incorporation.  The goal of this study was to 
determine any effect that the addition of the antibiotic 
tetracycline hydrochloride (0%, 2.5%, 5%, 10% by weight) 
would have on the mechanical properties of electrospun 
fibrinogen (110 mg/mL, 120 mg/mL, and 130 mg/mL 
concentrations).  Also, the time release of tetracycline 
from electrospun fibrinogen was investigated.  The results 
show no significant effect of tetracycline loading on the 
mechanical properties of electrospun fibrinogen under the 
conditions of this study.  The results of the release study 
demonstrate that initial tetracycline release is dependent 
upon loading percentage.  The release data also demonstrate 
that the amount of tetracycline released is approximately 
20-30% of the tetracycline in the original solution and 
that the release occurs within approximately 4 hours, with 
no significant release thereafter.  This study demonstrates 
the feasibility of tetracycline in electrospun fibrinogen 
xvi 
 
for the purposes of short term drug release in fibrinogen-
based technologies. 
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Introduction and Background 
 
 
 
 
The goal of tissue engineering is to create analogues 
to native tissue for the purpose of replacement or for the 
facilitation of repair.  Depending on application, the 
structure and composition of these analogues does differ.  
Regardless of application, the products of tissue 
engineering should not provoke a damaging immune response, 
should offer a successfully attractive framework for new or 
native cell establishment, and should possess mechanical 
and chemical properties similar to the replaced tissue.  
The purpose of this study was to incorporate tetracycline 
hydrochloride into a fibrinogen scaffold possibly to be 
used for in vivo wound repair or as a basis for the in 
vitro development of a tissue engineering scaffold.  The 
incorporation of an antibiotic such as tetracycline should 
assist in the resistance to infection of a maturing wound 
dressing or tissue scaffold, but the effects of its 
addition on the mechanical properties of the plain 
fibrinogen scaffold must be explored.  In addition, the 
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release of the tetracycline from the fibrinogen in solution 
should be of sufficient concentration and duration to 
elicit therapeutic effects. 
 
 
Tissue Engineering  
Tissue engineering is devoted to creating new tissue 
that can be accepted and utilized by the body.  A critical 
focus of tissue engineering is the framework with which the 
cells coexist, the extracellular matrix (ECM).  
Communication between the ECM and the cells guides growth, 
repair, and morphology1.     
 ECM analogues that more closely resemble native ECM 
will be better tolerated and incorporated in vivo.  One 
characteristic of ECM analogue closely related to success 
in vivo is fiber size.  When the size of fiber approaches 
that of the size of natural components of ECM, cells attach 
more easily, readily, and with better success.  Other 
critical aspect of successful biomimicking scaffolds is the 
minimization of an immune response.  This is affected 
greatly by the material from which the scaffold is 
constructed.  Although some synthetic polymers can provoke 
a negligible immune response, and others still can be 
3 
 
degraded and metabolized by the body, greater success is 
found in the use of natural polymers such as collagen, 
elastin, or fibrinogen.  Collagen is the major component of 
native ECM, and elastin exists in some various tissues of 
differing mechanical properties (i.e. blood vessels).  
Fibrinogen exists in tissues in the early stages of the 
repair of damaged tissue, and it yields fibrin, which may 
be thought as a ‘provisional matrix’. 
 The above tissue engineering concepts could be 
utilized to create or recreate native tissue such as skin, 
cornea, or liver.  For these applications, the most 
successful cell scaffold (collagen, elastin, fibrinogen, or 
blends) would be the best choice.  If the creation of a 
wound dressing is the target, fibrinogen is the obvious 
choice.  Not only would it have the advantage of being a 
native protein and possibly very acceptable to the native 
tissue, but fibrinogen also has the advantage of existing 
in the natural coagulation cascade, and so for a bleeding 
wound would have both wound healing and hemostatic effects.  
The possible incorporation of antibiotic into a wound 
dressing might offer better success in healing due to a 
reduction in infection. 
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Electrospinning 
 
Electrostatic spinning, or electrospinning, is a 
process that utilizes electrostatic forces to create small 
diameter fibers from the solution of a polymer.  The first 
successful development of electrospinning was in 1934 by 
Anton Formhals, who received a patent on the technology.  
Formhals electrospun small fibers of cellulose ester from a 
solvent of acetone and alcohol.2  The process can generate 
generous amounts of fibers at the sub-micron level, smaller 
in diameter than any standard extrusion process. 
Electrospinning is based on the electrostatic 
repulsion within a polymer solution, and the subsequent 
electrostatic attraction of the polymer solution (or its 
solute) to a grounded electrode.  It is a variant of 
electrospraying, where droplets of charged solution are 
attracted to a grounded electrode by an external electric 
field.  Electrospinning succeeds in the creation of fibers, 
rather than droplets that leave the charged solution.  
During electrospinning, a solution of polymer forms a 
droplet at the end of a capillary tube, or syringe needle, 
in this setup.  The droplet is maintained by the surface 
tension within the solution, and the applied electric field 
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to the solution forms the droplet into a “Taylor cone”, as 
the electric repulsion begins to overcome the surface 
tension.  When the electric repulsion within the solution 
reaches a critical value, a charged jet of the solution 
leaves the Taylor cone.3  This jet, attracted to the 
grounded electrode, becomes more concentrated in both 
solute and charge density as the solvent evaporates.  
Progressively, a thin charged fiber is left behind that 
travels to the ground electrode. A diagram of an 
electrospinning apparatus is shown below (Figure 1). 
 
 
Figure 1 : Schematic of electrospinning apparatus 
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The efficacy of this process, as well as the final 
fiber product, are affected by a litany of factors, 
including, but not limited to solution polymer 
concentration, viscosity of solution, voltage between 
solution and ground electrode, the distance between the 
Taylor cone and the ground electrode, and environmental 
conditions such as humidity and temperature.4 
Electrospun fibers, because of their small diameters, 
have seen much interest not only in the textile field, but 
also in that of biomedical research.  The small diameter 
fiber is more attractive to cell attachment, because of its 
similarity in size to native ECM components, which allow 
for the cell to attach to several fibers in a more natural 
geometry, rather than the singular flattened orientation 
that an attached cell would experience on a large diameter 
fiber.  Much research had been conducted with synthetic 
resorbable polymers, such as PGA, and natural polymers, 
such as collagen and fibrinogen.5,6,7 These studies have 
shown the utility of electrospun polymers as scaffolds for 
tissue engineering. 
In addition, an electrospun mat of synthetic or 
natural polymer could be used as a vehicle for drug 
delivery.  The target drug could be incorporated into the 
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polymer solution to be spun, and should be uniformly 
distributed with the final mat product.  Other technologies 
for drug delivery have proven useful (films, slow-release 
pelletized formations, polymer disks), but none of these 
technologies would enjoy the full cell-friendly benefits of 
electrospun materials.8,9  A study by Kenawy et al. utilized 
electrospun (and film deposited) synthetic polymers with 
incorporated tetracycline and compared the release 
characteristics of the same to a film based commercial 
product.10  In this study, two synthetic polymers, 
poly(ethylene-co-vinylacetate) and poly(lactic acid), and a 
blend of the two, were electrospun with 5% tetracycline 
hydrochloride.  Samples of these mats were placed in a 
buffered solution, and the concentration of tetracycline in 
that solution was determined using spectroscopy.  These 
polymers were chosen for their success in medical products. 
The use of a natural polymer, such as fibrinogen, 
should remove much concern of immunogenicity and offer a 
more favorable attachment scaffold for in vivo infiltration 
of cells in such an application.  
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Fibrinogen 
 
Fibrinogen Structure 
 
 Fibrinogen is a large protein of mean molecular weight 
33600 kDa, with 95% of the molecular weight attributed to 
six amino acid chains (2 Aα, 2 Bβ, and 2 γ chains).  These 
six amino chains are arranged in two identical halves, each 
half consisting of a single Aα, single Bβ, and single γ 
chain, with disulfide bonds linking these chains and the 
two AαBβγ halves together (a total of 29 disulfide bonds).  
This arrangement often leads to fibrinogen described as a 
dimer of the AαBβγ monomer11.  The Aα chain is the largest 
of the three chains, with 610 amino acid residues.  The Bβ 
chain and γ chain have 461 and 411 residues, respectively.  
The Bβ chain and γ chain possess sites of bound 
carbohydrates, which account for approximately 5% of the 
molecular weight of fibrinogen12.  Extensive data regarding 
the sequencing and variance of inter-species fibrinogen 
exists, and is beyond the scope of this study, yet, further 
research may show some effect of varying sequences on 
biochemical activity. 
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Fibrinogen Function and Activity 
 Fibrinogen is a crucial component of the coagulation 
cascade.  When vascular injury occurs, the pathway leading 
to blood coagulation is activated.  There exist two 
different pathways of coagulation, the intrinsic and 
extrinsic pathways.  Both of the pathways involve 
sequential activation of different blood components, yet 
both arrive at the same destination, the activation of 
Factor X to Factor Xa.  It is here that the pathways 
converge, and where the common pathway begins.  The common 
pathway will be discussed in modest detail, for it is here 
where fibrinogen plays an important part as substrate.  A 
diagram of the common pathway is presented in Figure 2. 
10 
 
 
Figure 2 : Diagram of coagulation cascade 13 
 
Factor X is activated (Factor Xa) while attached to 
the membrane of platelets at the injury site.  The 
biochemical function of Factor Xa is that of a serine 
protease, a chemical capable of breaking the amino acid 
backbone of a protein at a specific location.  Platelet-
attached Factor Xa forms a complex with another blood-borne 
component, Factor Va, and, in the presence of calcium, 
converts prothrombin to thrombin.  The protease action of 
Factor Xa is responsible for this conversion, assisted by 
11 
 
the cofactors Va and free calcium.  It is thrombin that 
truly controls coagulation, through two distinct actions.  
Thrombin activates yet another inactive blood component, 
Factor XIII to Factor XIIIa.  Thrombin also cleaves small 
peptide chains from the fibrinogen molecule to form soluble 
fibrin.12   
The action of thrombin on fibrinogen is targeted at 
portions of the amino acid backbone of the N-terminal end 
of the Aα and Bβ chains of fibrinogen, releasing 
fibrinopeptides A and B (FRPA and FRPB).  These 
fibrinopeptides are used as indicators of thrombin activity 
in laboratory tests.  The absence of these fibrinopeptides 
exposes regions on the original fibrinogen molecule (now 
fibrin) that form weak hydrogen bonds with like molecules, 
forming a loose clot at the injury site.12  The presence of 
Factor XIIa (the other thrombin-activated component) 
creates covalent bonds between fibrin molecules through 
transglutaminase activity, forming an insoluble fibrin 
clot14. The now insoluble fibrin clot traps platelets as the 
clot accumulates at the injury site. 
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Fibrinogen in Tissue Engineering 
 Because of the native appearance of fibrinogen to 
cells of the body, it is possible that fibrinogen could be 
utilized as a possible scaffold material for tissue 
engineering.  Upon exposure to thrombin, fibrinogen will 
yield fibrin, which is the first ECM that healing tissue 
will possess.  The fibrin clot offers stability and 
structure to the reforming tissue.  The fibrinopeptides 
cleaved from fibrinogen signal immune and endothelial cells 
to the site of injury, beginning the healing process via 
inflammatory response and angiogenesis15.  Other invading 
cells begin to digest the provisional fibrin plug and 
deposit permanent ECM materials such as collagen.16  More so 
than collagen or elastin, and certainly any synthetic 
polymer, fibrin should be the ideal healing scaffold for a 
wound, since it is the material that tissue would lay down 
naturally.  Many studies have been documented showing the 
effectiveness of the fibrin matrix is supporting cell 
growth and tissue development in musculoskeletal, 
epithelial, and urological applications.15  
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Fibrin-Based Technologies 
 The use of fibrin in wound treatment is storied, with 
reporting of such dating to 1909 by Bergel, who used dried 
plasma to arrest surgical bleeding.  Patches of pure fibrin 
have documented use in the decade to follow.  Early uses of 
fibrin included aid to skin grafting and nerve repair.17  
The usage of fibrin/fibrinogen products is somewhat clouded 
today due to possible transmission of viruses from a 
natural blood product, which led to an FDA ban on usage of 
pooled fibrinogen concentrates in 1978, leaving American 
clinicians with screened blood-bank and autologous blood as 
the sole source for fibrin products.18   
 The current fibrin-based products come in two forms, 
dry and liquid.  Both involve simultaneous application of 
fibrinogen and thrombin, sometimes with the addition of 
Factor XIII and calcium.  The dry product contains 
fibrinogen and thrombin, in a freeze-dried or frozen state, 
to prevent their reacting.  Stored in air-tight packaging, 
this product will yield fibrin upon exposure to air, and 
more appropriately, to a wound.  The United States Army has 
funded and overseen development of a technology similar to 
this for use on the battlefield.19  The liquid product is 
delivered as a simultaneous spray upon the wound of 
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fibrinogen and thrombin, forming a layer of fibrin that 
immediately clots the bleed.  Both technologies show great 
efficacy in their ability to deliver concentrations of 
these proteins at levels much higher than in blood.20  Both 
of these products, however, have their drawbacks.  The dry 
sealant has difficulty in handling because of its 
activation upon exposure to moisture (even humid air will 
begin the reaction).  The liquid version has a long 
preparation time because of the necessary dissolution of 
components, and therefore would not be optimal in an 
emergency setting. 
 
Possible Fibrinogen-Based Technology 
 If fibrinogen alone is used as the substrate for 
fibrin, the stability, ease of use, and longevity of the 
product is increased.  Without simultaneous thrombin 
administration, the fibrinogen-based product is reliant 
upon the thrombin of the wound for the formation of fibrin.  
However, the rapid attainment of fibrin with better 
handling could make such a product more viable and 
practical.  With the technology of electrospinning, an 
electrospun fibrinogen wound dressing would have the added 
benefit of small fiber diameter which could accelerate 
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wound healing.  Wnek et al. demonstrated the feasibility of 
electrospinning fibrinogen through the determination of an 
appropriate addition (10 X MEM) to the common 
electrospinning solvent HFP.10 Once the appropriate solvent 
was determined, Wnek et al. electrospun different 
concentrations of bovine fibrinogen and measured the fiber 
diameters of the final product using SEM microscopy and 
image processing software.  Their results indicated that 
fiber diameter could be controlled by the adjustment of the 
concentration of the spinning solution.
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Tetracycline 
 
Structure and Usage 
 
 Tetracyclines encompass a large group of antibiotics 
of similar structure and action.   The basic structure is 
one of four fused six carbon rings, with several positions 
that carry different functional groups depending on the 
particular tetracycline species.  The first isolated 
tetracycline was chlortetracycline (aureomycin), which was 
isolated from Streptomyces aureofaciens in 1948 by Benjamin 
Duggar.  The removal of the chlorine from the 7 position of 
chlortetracycline yielded tetracycline.  Tetracycline is 
considered the first drug that outperformed the natural 
drug source from which it originated.  This isolation is 
credited to Lloyd Conover in 1955.21  Other members of the 
family include oxytetracycline, doxycycline, and 
demeclocycline.22  The structure of tetracycline is shown in 
Figure 3.  It exists in use as a hydrochloride salt to 
increase solubility.  Tetracycline alone is a basic 
compound.  Widely used as an oral antibiotic, tetracyclines 
had the largest antimicrobial index of known antibiotics 
until the 1950s.23  
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Figure 3 : Tetracycline structure24 
 
Method of Action  
The tetracyclines are mostly bacteriostatic, damaging 
the ability of bacteria to reproduce, and are therefore 
only effective on those bacteria in stages of reproduction.  
Tetracyclines work by inhibiting protein synthesis in 
bacteria by binding to the 30S ribosome, thereby halting 
the progressive translation of proteins.  Considered very 
effective against E. Coli, bacterial ulcers and many 
topical infections, tetracyclines find use today in 
prophylaxis of acne, topical anti-inflammatory applications 
and in dental implants.25 
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Project Synopsis 
 This project explores the effect of tetracycline 
hydrochloride on the mechanical properties of electrospun 
fibrinogen, and the release of tetracycline from the same.  
Tetracycline was added to the solutions at the beginning of 
the electrospinning process, and the products of the 
electrospinning were subjected to mechanical testing.  
Also, time studies were conducted of independent samples of 
various preparations of fibrinogen/tetracycline to observe 
the release of the drug into a buffered saline solution.  
The intended outcomes of this research were to observe and 
quantify any change in mechanical properties because of 
tetracycline loading, as well as to observe and report the 
effects of different fibrinogen concentrations and 
tetracycline loading on the release of the drug from the 
electrospun mats. 
  
19 
 
 
Materials and Methods 
 
Solution Preparation 
 Due to the small mass of tetracycline hydrochloride to 
be added to fibrinogen solutions, stock mixtures of bovine 
fibrinogen (Sigma-Aldrich) and tetracycline (Sigma-Aldrich) 
in appropriate proportions were prepared in advance.  These 
mixtures offered greater precision in solution preparation.  
All necessary calculations insured the desired 
concentration of fibrinogen in each preparation.  Solutions 
of fibrinogen in concentrations of 110 mg/mL, 120 mg/mL, 
and 130 mg/mL were prepared with tetracycline weight 
percentages of 2.5%, 5%, and 10%.  In addition, pure 
fibrinogen solutions were prepared for mechanical analysis 
comparison and release controls.  The 
fibrinogen/tetracycline mixture was dissolved in a solution 
of 90% HFP and 10% 10 X MEM.  The volume of solvent for 
each preparation was 6 mL (5.4 mL HFP + 0.6 mL 10 X MEM).   
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Electrospinning 
In this setup, the solutions of fibrinogen with 
varying weight percentages of tetracycline were placed in 5 
mL syringes with 18 gauge blunt needles.  A syringe pump 
(KD Scientific) was used to maintain a measured flow rate.  
The flow rate of the pump was set at 2.0 mL/hr, with minor 
adjustments during individual spins for the purpose of 
optimizing the spinning process and minimizing waste.  A 
high voltage power supply (Spellman CZE100R, Spellman High 
Voltage Electronics Corporation) imparted a voltage of 22 
kV at the syringe needle.  The electrospun fibers were 
collected on a rotating stainless steel mandrel of length 
75 mm, width 25 mm, and thickness 4 mm, which also served 
as the ground electrode as mentioned earlier.  The mandrel 
was rotated at a rotational velocity of approximately 340 
rpm, and was also translated before the needle tip with a 
rectilinear velocity of approximately 75 mm/s.  The 
distance from the needle tip to the mandrel was 10 cm. 
The spinning process was conducted in a low-light 
environment because of the light-sensitive nature of 
tetracycline.  Fibers were collected on the mandrel until 
the syringe was devoid of solution, and the 
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fibrinogen/tetracycline mats were removed from the mandrel, 
wrapped in heavy foil to minimize light exposure, and 
stored at -20 degrees C until needed. 
  
Materials Testing 
For materials testing, samples of the preparation were 
trimmed into a “dogbone” profile in order to minimize grip 
effects, and to create a region of probable failure of 
known geometry for calculation of modulus and peak stress.  
The samples were 18.6 mm in length and 6.2 mm in width at 
their ends (grip attachment), narrowing to width 2.8 mm in 
the center of the sample (probable failure region).  The 
samples from each preparation (including pure fibrinogen) 
were subjected to uniaxial tensile testing using a MTS 
Bionix 200 testing station with a strain rate of 10 mm/min, 
and with a sampling rate of 20 Hz.  Samples were tested in 
both a dry state, and after immersion in PBS for twenty 
minutes.  Modulus, breaking strain, and peak stress were 
recorded. 
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Materials Characterization 
 Samples of mats spun from each preparation were 
prepared for scanning electron microscopy (SEM).  The 
samples of each mat were affixed to an electron microscopy 
stud.  As the mats are completely dry when spun, the only 
necessary step was sputter coating for the imaging process 
to be conducted.  SEM images were obtained with a JEOL JSM-
820 microscope at 4000x magnification.  The images obtained 
from SEM were scanned into digital computer images.  
UTHSCSA ImageTool Version 2.0 was used to determine the 
diameters of sixty sample fibers in each preparation for 
comparison across concentrations and loading percentages.  
In addition, the area of thirty pores was determined with 
ImageTool.  These values were averaged and standard 
deviations calculated. 
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Short Term and Long Term Release Protocol 
To study release, samples of each preparation were 
obtained.  These samples were harvested from each mat using 
a hole punch with diameter 6.35 mm.  The shape of every 
sample was identical, but the thickness varied slightly 
with each spin, and within each mat.  An average mass for a 
single sample punch was determined using the total weight 
of samples from a mat, and the number of sample punches.  
The samples were placed in 1 mL of PBS at 20 degrees 
Celsius.  All samples were independent – a given sample was 
studied at only one time point.  There were two time 
courses studied for release properties – a short time 
course of 128 min (8 time events) and a long time course of 
7 days (8 time events).  The short time course allowed for 
the collection of data regarding the initial surface 
dissolution and early release of tetracycline from the 
mats, a behavior overlooked when the first time sample is 
at after such dissolution has taken place.  From this 
study, that period of rapid dissolution was approximately 
an hour in length.  For the short time course, data were 
collected at 1, 2, 4, 8, 16, 32, 64, and 128 minutes.   For 
the longer time course, data were collected at 1, 4, 14, 
24, 48, 72, 120, and 168 hours.  For all release studies, 
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there existed triplicate independent samples for each time 
event.  This was done to minimize any error from non-
uniformity in the electrospun mats from which the samples 
came.  Also, for each short term time event, three 200 µL 
samples of the release solution were obtained, in an effort 
to avoid any collection error.  Four samples were obtained 
from each long term time event.  This offered nine (or 
twelve) values for each preparation at a given release 
time.  All solution samples for spectrophotometry were 
placed in a 96 well culture plate. 
 Tetracycline concentration in the solutions was 
determined using spectrophotometry.  A Molecular Devices 
Spectramax Plus spectrophotometer was used to obtain 
absorbances.  A standard curve was generated from known 
concentrations of tetracycline (0 µg/mL to 150 µg/mL) in PBS 
and corresponding absorbances at 360 nanometers.  This 
allowed for calculation of tetracycline concentration in 
unknown samples.  From the concentration (via absorbance 
standard curve), the defined volume in each sample well (1 
mL), and the spectrophotometer sample volume (200 
microliters), the amount of tetracycline released into 
solution by the samples could be determined.  With the 
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assumption that the weight percentage of tetracycline would 
be the same in the sample as it were in solution (i.e., if 
no disproportionate loss of tetracycline occurred between 
syringe to sample), the percentage release could be 
calculated with the mass of tetracycline in solution and 
the original mass of the sample.  The percentage release, 
even with the usage of the average mass calculation 
mentioned above, offers a better comparison of behaviors 
between preparations, as all spins were not identical, 
leading to variation among and within the sample groups.  
Such variation was minimized through identical geometry of 
samples (6.35 mm circles) and through screening of obvious 
incongruities within and among samples (i.e. portions of 
mats that were egregiously thin or damaged were not 
sampled). 
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Analytical Methods 
 
 
Mechanical Data 
 Analysis of Variance (ANOVA) was utilized to observe 
any statistical differences between the mechanical 
properties of modulus, breaking strain, and peak stress 
across different loading percentages for each 
concentration.  These properties for given concentrations 
of fibrinogen and tetracycline were compared using analysis 
of variance.  Analysis of variance is a statistical test 
that compares the variation within a group to the variation 
among groups.  A positive ANOVA indicates that the 
differences among groups are more substantial than would be 
expected by chance alone.  If differences among the sample 
groups were found, Tukey’s W was used to determine which 
values were significantly different.  Comparisons were made 
among preparations of the same fibrinogen concentration 
with different tetracycline loading, and among the average 
values of preparations with the same fibrinogen 
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concentration.  An alpha level of 0.05 was selected a 
priori for all statistical tests.  
 
Materials Characterization 
 ANOVA was also used to determine any difference in 
average diameter between preparations of identical 
fibrinogen concentrations with different tetracycline 
loading percentages.  Again, Tukey’s W was used to 
determine which preparations, if any, differed from each 
other.  In addition, average fiber diameters of all 
preparations of a given fibrinogen concentration were 
analyzed to determine any difference among samples of 
differing fibrinogen concentrations.  The same procedures 
were conducted regarding pore size. 
 
Release 
 From each time event, the absorbance at 360 nm was 
recorded.  A standard curve of absorbance of known 
tetracycline concentrations at 360 nm allowed for the 
calculation of concentration from absorbance (Figure 39).  
Also, from the volume of solution introduced into each 
plate well, the mass of tetracycline released into solution 
could be determined.  With the mass of tetracycline 
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released and the mass of the sample itself, the percentage 
of tetracycline released could be calculated. 
 For the short term release portion of the study, each 
of the triplicate samples for a time event was sampled 
three times, creating nine data values for each time event.  
For the long term release portion of the study, each of the 
triplicate samples was sampled four times, creating twelve 
data values.  This variation allowed for more precise 
measurements to be taken during a period of relatively 
lower release. These values were averaged, and standard 
deviations were calculated. 
 The concentration values of each time event were 
compared across different tetracycline loading percentages 
for a given fibrinogen concentration.  ANOVA was used to 
determine if these samples at given time index did differ 
significantly – if so, Tukey’s W test was used to assess 
which values were significantly different at α = 0.05.  
Also, for a given run of release, the data values at all 
time indices for a given preparation were analyzed using 
ANOVA.  This would indicate if any significant release was 
occurring.  Upon significance of differing values, Tukey’s 
W test was again analyzed to determine which contiguous 
data points did not significantly differ, thereby 
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indicating the absence of release at that time, and 
possibly beyond. 
 In an effort to normalize the release curves, the 
percentage of tetracycline released was calculated.  This 
allowed for a more illustrative comparison between 
different preparations, rather than simple concentration in 
the release solution.  The percentage data was used to 
compare all preparations to each other (using ANOVA and 
possible ancillary tests), as these data were independent 
of the mass of tetracycline in the sample. 
Those fibrinogen samples without tetracycline showed 
no change over time in release solution absorbance in 
preliminary testing.  Also, the standard curve for 
absorbance was obtained with solutions of known 
concentration of tetracycline in PBS.  Therefore, the data 
obtained by spectrophotometry were already controlled for 
presence of fibrinogen and PBS. 
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Results 
 
 
 
 
Fiber Diameter and Pore Area 
 
 After electrospinning, a small sample of each 
preparation was obtained for scanning electron microscopy 
(SEM).  Sample photographs follow (Figures 4a-4l).   
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 Figure 4a : SEM micrograph at 4000x 
magnification of 110 mg/mL 
fibrinogen with 0% tetracycline by 
weight 
 Figure 4b : SEM micrograph at 4000x 
magnification of 110 mg/mL fibrinogen 
with 2.5% tetracycline by weight 
 Figure 4c : SEM micrograph at 4000x 
magnification of 110 mg/mL 
fibrinogen with 5% tetracycline by 
weight 
 Figure 4d : SEM micrograph at 4000x 
magnification of 110 mg/mL fibrinogen 
with 10% tetracycline by weight 
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Figure 4e : SEM micrograph at 4000x 
magnification of 120 mg/mL 
fibrinogen with 0% tetracycline by 
weight 
Figure 4f : SEM micrograph at 4000x 
magnification of 120 mg/mL fibrinogen 
with 2.5% tetracycline by weight 
 
 
Figure 4g : SEM micrograph at 4000x 
magnification of 120 mg/mL 
fibrinogen with 5% tetracycline by 
weight 
 
 
Figure 4h : SEM micrograph at 4000x 
magnification of 120 mg/mL fibrinogen 
with 10% tetracycline by weight 
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Figure 4i : SEM micrograph at 4000x 
magnification of 130 mg/mL 
fibrinogen with 0% tetracycline by 
weight 
Figure 4j : SEM micrograph at 4000x 
magnification of 130 mg/mL fibrinogen 
with 2.5% tetracycline by weight 
Figure 4k : SEM micrograph at 4000x 
magnification of 130 mg/mL 
fibrinogen with 5% tetracycline by 
weight 
Figure 4l : SEM micrograph at 4000x 
magnification of 130 mg/mL fibrinogen 
with 10% tetracycline by weight 
 
Figures 4a-4l: SEM micrographs of electrospun fibrinogen with and 
without tetracycline 
 
From these micrographs, values for average fiber 
diameter and pore size were determined using UTHSCSA 
ImageTool.  Tables of fiber diameter data (Table 1) and 
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pore area (Table 2) are provided. Average fiber diameter, 
average pore area, and standard deviations are provided. 
 
 Fiber Diameter (µm) 
Mean ± SD 
 Fibrinogen 110 mg/mL 
Fibrinogen 
120 mg/mL 
Fibrinogen 
130 mg/mL 
0 % Tetracycline 0.345 ± 0.086 0.479 ± 0.155 0.695 ± 0.227 
2.5 % Tetracycline 0.304 ± 0.112 0.448 ± 0.195 0.669 ± 0.219 
5 % Tetracycline 0.299 ± 0.114 0.442 ± 0.157 0.660 ± 0.234 
10 % Tetracycline 0.307 ± 0.104 0.452 ± 0.146 0.702 ± 0.238 
 
Table 1 :  Fiber diameter data for fibrinogen/tetracycline preparations 
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 Pore Area (µm
2) 
Mean ± SD 
 Fibrinogen 110 mg/mL 
Fibrinogen 
120 mg/mL 
Fibrinogen 
130 mg/mL 
0 % Tetracycline 2.475 ± 1.126 5.188 ± 2.037 7.198 ± 1.956 
2.5 % Tetracycline 2.919 ± 1.331 5.066 ± 2.272 6.737 ± 2.938 
5 % Tetracycline 2.483 ± 1.001 5.237 ± 2.685 6.571 ± 2.963 
10 % Tetracycline 2.686 ± 0.910 5.500 ± 2.225 6.740 ± 2.946 
 
 
Table 2 : Pore area data for fibrinogen/tetracycline preparations 
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 The following figures present the data in graphical 
form.  Error bars account for one standard deviation. 
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Figure 5 : Fiber Diameter by fibrinogen concentration and tetracycline 
weight percentage 
37 
 
 
Figure 6 :  Pore area by fibrinogen concentration and tetracycline 
weight percentage 
 
 
 An analysis of variance indicated no significant 
difference (α = 0.05) in either fiber diameter (Table 1) or 
pore area (Table 2) for varying tetracycline loading 
percentages at a given fibrinogen concentration.  However, 
an analysis of variance of average values of fiber 
diameters for a given fibrinogen concentration showed 
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significant differences across concentrations (P < 0.001).  
A Tukey’s W showed that each fiber diameter mean was 
significantly different pairwise, for each pair of 
concentrations (All P < 0.001).  Similarly, an analysis of 
variance showed significant differences in the average pore 
area values for the differing fibrinogen concentrations (P 
< 0.001), and Tukey’s W indicated that each fibrinogen 
concentration pore area mean was statistically different 
from the others. 
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Mechanical Data 
 From each preparation, samples were obtained for 
mechanical testing, under both dry and wet (saturated in 
PBS) conditions.  Modulus, breaking strain, and peak stress 
were recorded.  Stress is the quotient of the force acting 
upon a object and the cross-sectional area of the object, 
and provides a normalized force for use in comparing 
mechanical behaviors among different materials and 
differing shapes.  Peak stress is the highest stress 
experienced until the material begins to fail.  Strain is a 
measure of deformation of an object while acted upon by an 
external force.  Breaking strain is the maximum deformation 
of a material before it ruptures.  Modulus is a quantity 
that relates the response of a material (strain) to the 
application of outside stress.  It is a description of how 
stiff or flexible the material is.  The following graphs 
illustrate the data.  Confidence level for all statistical 
tests is α = 0.05. 
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Moduli of Dry Samples 
 
Figure 7 :  Modulus by Concentration and Percentage Tetracycline (Dry 
Sample) 
 
 An analysis of variance showed no significant 
difference in dry moduli (Figure 7) among different 
tetracycline loading percentages for a given fibrinogen 
concentration.  However, average values of dry moduli for a 
given fibrinogen concentration were significantly different 
from each other (P < 0.001).  Tukey’s W demonstrated 
significant differences among all average values of 
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fibrinogen concentrations (P < 0.001).  These significant 
differences indicate that the 130 mg/mL preparations 
possess higher moduli than the 120 mg/mL preparations, 
which in turn possess higher moduli than the 110 mg/mL 
preparations. 
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Breaking Strains of Dry Samples 
 
Figure 8 : Breaking Strain by Concentration and Percentage Tetracycline 
(Dry Sample) 
 
 An analysis of variance of dry breaking strain data 
(Figure 8) showed no significant differences in breaking 
strain across tetracycline loading percentages for a given 
fibrinogen concentration, nor any significant differences 
in breaking strain for differing fibrinogen concentrations. 
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Peak Stresses of Dry Samples 
 
Figure 9 : Peak Stress by Concentration and Percentage Tetracycline 
(Dry Sample) 
 
An analysis of variance showed no significant 
differences in peak stress due to differing percentages of 
tetracycline (Figure 9).  However, ANOVA returned a 
significant difference in average peak stress values among 
fibrinogen concentrations regardless of loading (P < 
0.001), and Tukey’s W found differences between 130 mg/mL 
preparations and 110 mg/mL preparations (P < 0.001), as 
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well as between 120 mg/mL preparations and 110 mg/mL (P < 
0.003).  In each case, the peak stress of dry 110 mg/mL 
fibrinogen concentrations was lower. 
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Moduli of Wet Samples 
 
Figure 10 :  Modulus by Concentration and Percentage Tetracycline (Wet 
Sample) 
 
An analysis of variance showed no significant 
differences in modulus due to differing percentages of 
tetracycline for wet samples (Figure 10).  However, ANOVA 
returned a significant difference in average modulus among 
fibrinogen concentrations regardless of loading (P = 
0.002), and Tukey’s W found differences between 120 mg/mL 
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preparations and 110 mg/mL preparations (P = 0.002), as 
well as between 130 mg/mL preparations and 110 mg/mL (P = 
0.01).  In each case, the modulus of wet 110 mg/mL 
fibrinogen concentrations was lower. 
47 
 
Breaking Strains of Wet Samples 
 
 
Figure 11 : Breaking Strain by Concentration and Percentage 
Tetracycline (Wet Sample) 
 
An analysis of variance showed no significant 
differences in breaking strain due to differing percentages 
of tetracycline for wet samples ( 
Figure 11).  However, ANOVA returned a significant 
difference in average breaking strain among fibrinogen 
concentrations regardless of loading (P = 0.005), and 
Tukey’s W found differences between 120 mg/mL preparations 
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and 110 mg/mL preparations (P = 0.03), as well as between 
130 mg/mL preparations and 110 mg/mL (P = 0.005).  In each 
case, the breaking strain of wet 110 mg/mL fibrinogen 
concentrations was lower than the other concentrations. 
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Peak Stress of Wet Samples 
 
 
Figure 12 : Peak Stress by Concentration and Percentage Tetracycline 
(Wet Sample) 
 
An analysis of variance showed no significant 
differences in peak stress due to differing percentages of 
tetracycline for wet samples (Figure 12).  However, ANOVA 
returned a significant difference in average peak stress 
among fibrinogen concentrations regardless of loading (P = 
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0.007), and Tukey’s W found significant differences between 
130 mg/mL preparations and 110 mg/mL preparations (P = 
0.016), as well as between 120 mg/mL preparations and 110 
mg/mL (P = 0.011).  In each case, the peak stress of wet 
110 mg/mL fibrinogen was lower. 
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Short Term Release 
The results for short term release follows for all 
preparations of fibrinogen with tetracycline.  For each 
fibrinogen concentration (110 mg/mL, 120 mg/mL, and 130 
mg/mL), there exist three different preparations, each with 
different loading percentages of tetracycline (2.5% w/w, 5% 
w/w, 10% w/w).  The results first report differences in 
release profiles for different tetracycline loading of a 
given fibrinogen concentration.  Then, concentration over 
the time course of the release run (1 min to 128 min) is 
analyzed to determine when significant release occurred.  
The percentage releases among the three preparations are 
compared to observe any differences among different loading 
of tetracycline.  Then the results are grouped by 
tetracycline loading to observe the effects of varying 
fibrinogen concentrations.  All analyses will utilize ANOVA 
and Tukey’s W, with the a priori significance level of α = 
0.05.   
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Release from 110 mg/mL Fibrinogen Preparations 
Concentration 
 
Figure 13 : Concentration versus time 110 mg/mL fibrinogen with 
tetracycline hydrochloride (1 min to 128 min) 
 
 
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0.16
0 20 40 60 80 100 120 140
Time (min)
Co
nc
en
tr
at
io
n 
(m
g/
mL
)
110 mg/mL with 2.5% 110 mg/mL with 5% 110 mg/mL with 10%
53 
 
Figure 13 shows the change in tetracycline 
concentration in the release solution over time for 110 
mg/mL fibrinogen samples.  Three different loading 
percentages of tetracycline are shown.  Analysis of 
variance of the tetracycline concentrations at each time 
point showed significant difference among the three 
tetracycline loading concentrations (all P < 0.001).  
Tukey’s W found that, for each time point, the release 
concentration of the 10% preparation was significantly 
higher than the 5% preparation (all P < 0.001), and that 
the release concentration of the 5% preparation was higher 
than that of the 2.5% preparation (all P < 0.001).  In 
other words, the three profiles in Figure 13 are 
significantly different. 
  For the 110 mg/mL fibrinogen with 2.5% tetracycline, 
ANOVA revealed that the concentrations from 1 min to 128 
min were significantly different (P < 0.001).  However, 
Tukey’s W indicated that the only significant difference 
between two successive values existed between 4 min and 8 
min (P < 0.001).  Therefore, any release after 8 min can 
not be considered significant. (See Table 20 in the 
Appendix for all pairwise P-values) 
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For the 110 mg/mL fibrinogen with 5% tetracycline, 
ANOVA revealed that the concentrations from 1 min to 128 
min were significantly different (P < 0.001).  However, 
Tukey’s W found that the only significant differences in 
concentration observed between successive time points were 
between times 2 min and 4 min (P = 0.004), 4 min and 8 min 
(P < 0.001), and between 64 min and 128 min (P = 0.042).  
Therefore, there was significant release from 2 min to 8 
min and from 64 min to 128 min. (See Table 21 in Appendix 
for all pairwise P-values) 
For the 110 mg/mL fibrinogen with 10% tetracycline, 
ANOVA revealed that the concentrations from 1 min to 128 
min were significantly different (P < 0.001).   The 
significant differences in concentration observed between 
contiguous time points by Tukey’s W were between times 2 
min and 4 min (P < 0.001), 4 min and 8 min (P = 0.001), 8 
min and 16 min (P = 0.02), and 32 min and 64 min (P = 
0.042).  This indicated that significant release occurred 
from time 2 min to 16 min.  There was further significant 
release from 32 min to 64 min. (See Table 22 in Appendix 
for all pairwise P-values) 
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Release from 110 mg/mL Fibrinogen Preparations 
Percentage Release 
 
Figure 14 : Percentage released versus time for 110 mg/mL fibrinogen 
with tetracycline hydrochloride (1 min to 128 min) 
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Figure 14 shows the percentage release over time from 
preparations of 110 mg/mL fibrinogen with three different 
tetracycline loading concentrations.  These percentage 
release profiles are identical in shape to the 
concentration graphs of Figure 13.  The concentrations have 
been converted to percentage of tetracycline released by 
using the average mass of the sample, and the 
concentrations of Figure 13 as indicated in the Methods.  
The calculation of percentage release serves as a 
normalized view of release, independent of mass, and, 
therefore allows for a better comparison of release from 
different preparations.  
 Analysis of variance at each time event indicated that 
at all time points other than 16 min and 128 min, there 
existed significant difference among the samples.  These 
results are provided below in Table 3.  At time points 
where ANOVA indicated differences among the percentage 
values, Tukey’s W was used to find which pairs of 
percentages were different. These results are also provided 
in Table 3. In short, the percentage release from the 
preparation with 10% tetracycline was significantly higher 
than the 2.5% preparation for all times when significant 
differences were observed.  Also, the 10% preparation also 
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was significantly higher than the 5% preparation at times 1 
min, 2 min, and 64 min.  At time 4 min, all percentage 
release values were significantly different. 
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Time 
Difference 
among samples 
(ANOVA) 
Pairwise Differences   
(Tukey’s W) 
1 min Yes, P < 0.001 10% > 5% (P < 0.001) 10% > 2.5% (P = 0.001) 
2 min Yes, P < 0.001 10% > 5% (P < 0.001)  10% > 2.5% (P = 0.001) 
4 min Yes, P < 0.001 
10% > 5% (P < 0.001) 
10% > 2.5% (P < 0.001) 
 5% > 2.5% (P < 0.001) 
8 min Yes, P = 0.006 10% > 2.5% (P = 0.004) 
16 min None None 
32 min Yes, P = 0.049 10% > 2.5% (P < 0.001) 
64 min Yes, P < 0.001 10% > 5% (P < 0.001) 10% > 2.5% (P < 0.001) 
128 min None None  
 
Table 3 : P – values for ANOVA and Tukey’s W for 110 mg/mL samples (1 
min to 128 min)  
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Release from 120 mg/mL Fibrinogen Preparations 
Concentration 
 
 
Figure 15 : Concentration versus time 120 mg/mL fibrinogen with 
tetracycline hydrochloride (1 min to 128 min) 
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percentages of tetracycline are shown.  Analysis of 
variance of the tetracycline concentrations at each time 
point showed significant difference among the three 
tetracycline loading concentrations (all P < 0.001).  
Tukey’s W found that, for each time point, the release 
concentration of the 10% preparation was significantly 
higher than the 5% preparation (all P < 0.001), and that 
the release concentration of the 5% preparation was higher 
than that of the 2.5% preparation (all P < 0.001).  In 
other words, the three profiles in Figure 15 are 
significantly different. 
  For the 120 mg/mL fibrinogen with 2.5% tetracycline, 
ANOVA revealed that the concentrations from 1 min to 128 
min were significantly different (P < 0.001).  However, 
Tukey’s W indicated that only significant difference 
between two successive values existed between 4 min and 8 
min (P < 0.001).  Therefore, significant release only 
occurred between 4 min and 8 min. (See Table 23 in the 
Appendix for all pairwise P-values) 
For the 120 mg/mL fibrinogen with 5% tetracycline, 
ANOVA revealed that the concentrations from 1 min to 128 
min were significantly different (P < 0.001).  However, 
Tukey’s W found that the only significant differences in 
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concentration observed between successive time points were 
between times 2 min and 4 min (P = 0.004), 4 min and 8 min 
(P < 0.001), and between 64 min and 128 min (P = 0.042).  
Therefore, there was significant release from 2 min to 8 
min and from 64 min to 128 min. (See Table 24 in Appendix 
for all pairwise P-values) 
For the 120 mg/mL fibrinogen with 10% tetracycline, 
ANOVA revealed that the concentrations from 1 min to 128 
min were significantly different (P < 0.001).   The 
significant differences in concentration observed between 
contiguous time points by Tukey’s W were between times 1 
min and 2 min (P < 0.001), 2 min and 4 min (P < 0.001), 4 
min and 8 min (P = 0.001), 8 min and 16 min (P = 0.02), and 
32 min and 64 min (P = 0.042).  This indicated that 
significant release occurred from time 1 min to 16 min.  
There was further significant release from 32 min to 64 
min. (See Table 25 in Appendix for all pairwise P-values) 
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Release from 120 mg/mL Fibrinogen Preparations 
Percentage Release 
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Figure 16 : Percentage released versus time 120 mg/mL fibrinogen with 
tetracycline hydrochloride (1 min to 128 min) 
 
Figure 16 shows the percentage release over time from 
preparations of 120 mg/mL fibrinogen with three different 
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tetracycline loading concentrations.  These percentage 
release profiles are identical in shape to the 
concentration graphs of Figure 15.  The concentrations have 
been converted to percentage of tetracycline released by 
using the average mass of the sample, and the 
concentrations of Figure 15 as indicated in the Methods.  
The calculation of percentage release serves as a 
normalized view of release, independent of mass, and, 
therefore allows for a better comparison of release from 
different preparations.  
Analysis of variance at each time event indicated that 
at all time points other than 1 min and 128 min, there 
existed significant difference among the samples.  These 
results are provided below in Table 4.  At time points 
where ANOVA indicated differences among the percentage 
values, Tukey’s W was used to find which pairs of 
percentages were different. These results are also provided 
below in Table 4.  In summary, the percentage release from 
the preparation with 10% tetracycline was significantly 
higher than the 2.5% preparation for all times when 
significant differences were observed, with the exception 
of time 2 min.  Additionally, the 10% preparation also was 
significantly higher than the 5% preparation at times 2 
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min, 32 min, and 64 min.  The 5% preparation was 
significantly higher than the 2.5% preparation at 2 min and 
4 min.  At time 16 min, all percentage release values were 
significantly different, with preparation of higher 
tetracycline percentages demonstrating greater release.  
 
Time 
Difference 
among samples 
(ANOVA) 
Pairwise Differences   
(Tukey’s W) 
1 min None None 
2 min Yes, P < 0.001 10% > 5% (P < 0.001)  5% > 2.5% (P < 0.001) 
4 min Yes, P < 0.001 10% > 2.5% (P < 0.001) 5% > 2.5% (P = 0.023) 
8 min Yes, P = 0.004 10% > 2.5% (P = 0.004) 
16 min Yes, P < 0.001 
10% > 5% (P < 0.001) 
 10% > 2.5% (P < 0.001) 
 5% > 2.5% (P = 0.031) 
32 min Yes, P = 0.001 10% > 5% (P = 0.038)  10% > 2.5% (P = 0.003) 
64 min Yes, P = .001 10% > 5% (P < 0.001)  10% > 2.5% (P < 0.001)     
128 min None None 
 
Table 4 : P – values for ANOVA and Tukey’s W for 120 mg/mL samples (1 
min to 128 min) 
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Release from 130 mg/mL Fibrinogen Preparations 
Concentration 
 
Figure 17 : Concentration versus time 130 mg/mL fibrinogen with 
tetracycline hydrochloride (1 min to 128 min) 
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percentages of tetracycline are shown.  Analysis of 
variance of the tetracycline concentrations at each time 
point showed significant difference among the three 
tetracycline loading concentrations (all P < 0.001).  
Tukey’s W found that, for each time point, the release 
concentration of the 10% preparation was significantly 
higher than the 5% preparation (all P < 0.001), and that 
the release concentration of the 5% preparation was higher 
than that of the 2.5% preparation (all P < 0.001).  In 
other words, the three profiles in Figure 17 are 
significantly different. 
  For the 130 mg/mL fibrinogen with 2.5% tetracycline, 
ANOVA revealed that the concentrations from 1 min to 128 
min were significantly different (P < 0.001).  However, 
Tukey’s W indicated that only significant difference 
between two successive values existed between 16 min and 32 
min (P < 0.01).  Therefore, significant release only 
occurred between 16 min and 32 min, and no significant 
release occurred thereafter. (See Table 26 in the Appendix 
for all pairwise P-values) 
For the 130 mg/mL fibrinogen with 5% tetracycline, 
ANOVA revealed that the concentrations from 1 min to 128 
min were significantly different (P < 0.001).  However, 
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Tukey’s W found that the only significant differences in 
concentration observed between successive time points were 
between times 2 min and 4 min (P = 0.006), 32 min and 64 
min (P < 0.001), and between 64 min and 128 min (P < 
0.001).  Therefore, there was significant release from 2 
min to 8 min and from 32 min to 128 min. (See Table 27 in 
Appendix for all pairwise P-values) 
For the 130 mg/mL fibrinogen with 10% tetracycline, 
ANOVA revealed that the concentrations from 1 min to 128 
min were significantly different (P < 0.001).   The 
significant differences in concentration observed between 
contiguous time points by Tukey’s W were between times 1 
min and 2 min (P < 0.001), 2 min and 4 min (P = 0.004), 8 
min and 16 min (P < 0.001), and 16 min and 32 min (P = 
0.018).  This indicated that significant release occurred 
from time 1 min to 4 min.  There was further significant 
release from 8 min to 32 min, but no significant release 
thereafter. (See Table 28 in Appendix for all pairwise P-
values) 
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Release from 130 mg/mL Fibrinogen Preparations 
Percentage Release 
Figure 18 : Percentage released versus time 130 mg/mL fibrinogen with 
tetracycline hydrochloride (1 min to 128 min) 
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concentration graphs of Figure 17.  The concentrations have 
been converted to percentage of tetracycline released by 
using the average mass of the sample, and the 
concentrations of Figure 17 as indicated in the Methods.  
The calculation of percentage release serves as a 
normalized view of release, independent of mass, and, 
therefore allows for a better comparison of release from 
different preparations.  
Analysis of variance at each time event indicated that 
at all time points other than 2 min, 8 min, and 128 min, 
there existed significant difference among the samples.  
These results are provided below in Table 5.  At time 
points where ANOVA indicated differences among the 
percentage values, Tukey’s W was used to find which pairs 
of percentages were different. These results are also 
provided below in Table 5.  In summary, the percentage 
release from the preparation with 10% tetracycline was 
significantly higher than the 2.5% preparation at times 1 
min, 4 min, 64 min, and 128 min, as well as higher than the 
5% preparation at times 2 min, and 128 min.  The 5% 
preparation was significantly different from the 2.5% 
preparation at 1 min and 32 min.  At 1 min, all percentage 
release values were significantly different. 
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Time 
Difference 
among samples 
(ANOVA) 
Pairwise Differences   
(Tukey’s W) 
1 min Yes, P < 0.001 
10% > 2.5% (P < 0.001) 
10% > 5% (P = 0.029) 
5% > 2.5% (P= 0.003) 
2 min None None  
4 min Yes, P = 0.018 10% > 2.5% (P < 0.001) 5% > 2.5% (P = 0.023) 
8 min None None 
16 min None None 
32 min Yes, P = 0.01 5% > 2.5% (P = 0.007) 
64 min Yes, P = 0.025 10% > 2.5% (P = 0.028) 
128 min Yes, P <  0.001 10% > 2.5% (P = 0.002) 10% < 5% (P = 0.003) 
 
Table 5 : P – values for ANOVA and Tukey’s W for 130 mg/mL samples (1 
min to 128 min) 
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Release from 2.5% Tetracycline Preparations 
Concentration 
 
Figure 19 : Concentration versus time for preparations with 2.5% 
Tetracycline (1 min to 128 min) 
 
Figure 19 shows the change in tetracycline 
concentration in the release solution over time for samples 
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tetracycline concentrations at each time point showed 
significant difference among the three fibrinogen 
concentrations (all P < 0.01).  Tukey’s W found 
significance differences between pairs of concentrations at 
all times.  These results are summarized in Table 6.  In 
summary, the 130 mg/mL and 120 mg/mL preparations exhibited 
significantly higher release than the 110 mg/mL 
preparations at times 1 min and 2 min.  From that point on, 
the general trend shows significantly higher release from 
the 120 mg/mL preparations.  The 110 mg/mL preparations 
also exhibited greater release than the 130 mg/mL 
preparations at 8 min, 16 min, 64 min, and 128 min. 
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Table 6 : P – values for ANOVA and Tukey’s W for release concentration 
of samples with 2.5 % tetracycline loading (1 min to 128 min) 
Time 
Difference 
among samples 
(ANOVA) 
Pairwise Differences (Tukey’s W) 
1 min Yes, P < 0.001 130 mg/mL > 110 mg/mL (P < 0.001) 120 mg/mL > 110 mg/mL (P < 0.001) 
2 min Yes, P < 0.001 130 mg/mL > 110 mg/mL (P < 0.001) 120 mg/mL > 110 mg/mL (P < 0.001) 
4 min Yes, P = 0.009 120 mg/mL > 130 mg/mL (P = 0.006) 
8 min Yes, P < 0.001 120 mg/mL > 130 mg/mL (P < 0.001) 110 mg/mL > 130 mg/mL (P = 0.005) 
16 min Yes, P < 0.001 120 mg/mL > 130 mg/mL (P < 0.001) 110 mg/mL > 130 mg/mL (P = 0.005) 
32 min Yes, P < 0.001 120 mg/mL > 110 mg/mL (P = 0.018) 120 mg/mL > 130 mg/mL (P < 0.001) 
64 min Yes, P < 0.001 
110 mg/mL > 130 mg/mL (P < 0.001) 
120 mg/mL > 110 mg/mL (P = 0.011) 
120 mg/mL > 130 mg/mL (P < 0.001) 
128 min Yes, P < 0.001 
110 mg/mL > 130 mg/mL (P = 0.048) 
120 mg/mL > 110 mg/mL (P < 0.001) 
120 mg/mL > 130 mg/mL (P < 0.001) 
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Release from 2.5% Tetracycline Preparations 
Percentage Release 
 
Figure 20 : Percentage released versus time for preparations with 2.5% 
tetracycline (1 min to 128 min) 
 
Figure 20 shows the percentage release over time from 
preparations with 2.5% tetracycline loading for three 
different fibrinogen concentrations.  These percentage 
release profiles are identical in shape to the 
concentration graphs of Figure 19.  The concentrations have 
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been converted to percentage of tetracycline released by 
using the average mass of the sample, and the 
concentrations of Figure 19 as indicated in the Methods.  
The calculation of percentage release serves as a 
normalized view of release, independent of mass, and, 
therefore allows for a better comparison of release from 
different preparations.  
 Analysis of variance at each time event indicated that 
only at time points 1 min and 2 min, there existed 
significant differences among the samples.  These results 
are provided below in Table 7.  At time points where ANOVA 
indicated differences among the percentage values, Tukey’s 
W was used to find which pairs of percentages were 
different. In short, the percentage release from the 
preparation with 130 mg/mL fibrinogen exceeded that of 120 
mg/mL fibrinogen preparation at times 1 min and 2 min.  In 
addition the percentage release from the preparation with 
120 mg/mL fibrinogen was greater that of 110 mg/mL 
fibrinogen at those times.  From 4 min, the percentage 
release from the three preparations was not significantly 
different. 
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Table 7 : P – values for ANOVA and Tukey’s W for percentage release of 
samples with 2.5 % tetracycline loading (1 min to 128 min) 
 
Time 
Difference 
among samples 
(ANOVA) 
Pairwise Differences (Tukey’s W) 
1 min Yes, P < 0.001 
130 mg/mL > 110 mg/mL (P < 0.001) 
130 mg/mL > 120 mg/mL (P < 0.001) 
120 mg/mL > 110 mg/mL (P < 0.001) 
2 min Yes, P < 0.001 
130 mg/mL > 110 mg/mL (P < 0.001) 
130 mg/mL > 120 mg/mL (P = 0.040) 
120 mg/mL > 110 mg/mL (P = 0.001) 
4 min None None 
8 min None None 
16 min None None 
32 min None None 
64 min None None 
128 min None None 
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Release from 5% Tetracycline Preparations 
Concentration 
 
Figure 21 : Concentration versus time for preparations with 5% 
tetracycline (1 min to 128 min) 
 
Figure 21 shows the change in tetracycline 
concentration in the release solution over time for samples 
with 5% tetracycline loading.  Three different fibrinogen 
concentrations are shown.  Analysis of variance of the 
tetracycline concentrations at each time point showed 
significant difference among the three fibrinogen 
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concentrations (all P < 0.001).  Tukey’s W found 
significance differences between pairs of concentrations at 
all times.  These results are summarized in Table 8.  In 
summary, at times 1 min and 2 min, the 130 mg/mL and 120 
mg/mL fibrinogen preparations exhibited greater release 
than the 110 mg/mL preparation, with the release from 120 
mg/mL exceeded the 130 mg/mL preparation as well.  From 
that point on, the general trend shows significantly higher 
release from the 120 mg/mL preparations.  The 110 mg/mL 
preparations also exhibited greater release than the 130 
mg/mL preparations at 16 min and 32 min. 
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Table 8 : P – values for ANOVA and Tukey’s W for release concentration 
of samples with 5 % tetracycline loading (1 min to 128 min) 
Time 
Difference 
among samples 
(ANOVA) 
Pairwise Differences (Tukey’s W) 
1 min Yes, P < 0.001 
130 mg/mL > 110 mg/mL (P = 0.003) 
120 mg/mL > 110 mg/mL (P < 0.001) 
120 mg/mL > 130 mg/mL (P = 0.050) 
2 min Yes, P < 0.001 
130 mg/mL > 110 mg/mL (P < 0.001) 
120 mg/mL > 110 mg/mL (P < 0.001) 
120 mg/mL > 130 mg/mL (P < 0.001) 
4 min Yes, P < 0.001 120 mg/mL > 110 mg/mL (P < 0.001) 120 mg/mL > 130 mg/mL (P < 0.001) 
8 min Yes, P < 0.001 120 mg/mL > 130 mg/mL (P < 0.001) 
16 min Yes, P < 0.001 120 mg/mL > 130 mg/mL (P < 0.001) 110 mg/mL > 130 mg/mL (P < 0.001) 
32 min Yes, P < 0.001 
120 mg/mL > 110 mg/mL (P < 0.001) 
120 mg/mL > 130 mg/mL (P < 0.001) 
110 mg/mL > 130 mg/mL (P = 0.003) 
64 min Yes, P < 0.001 120 mg/mL > 110 mg/mL (P = 0.013) 120 mg/mL > 130 mg/mL (P < 0.001) 
128 min Yes, P < 0.001 120 mg/mL > 110 mg/mL (P < 0.001) 120 mg/mL > 130 mg/mL (P < 0.001) 
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Release from 5% Tetracycline Preparations 
Percentage Release 
 
Figure 22 : Percentage released versus time for preparations with 5% 
Tetracycline (1 min to 128 min) 
 
Figure 22 shows the percentage release over time from 
preparations with 5% tetracycline loading for three 
different fibrinogen concentrations.  These percentage 
release profiles are identical in shape to the 
concentration profiles of Figure 21.  The concentrations 
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have been converted to percentage of tetracycline released 
by using the average mass of the sample, and the 
concentrations of Figure 21 as indicated in the Methods.  
The calculation of percentage release serves as a 
normalized view of release, independent of mass, and, 
therefore allows for a better comparison of release from 
different preparations.  
 Analysis of variance at each time event indicated that 
at all times other than 64 min and 128 min, there existed 
significant difference among the samples.  These results 
are provided below in Table 9.  At time points where ANOVA 
indicated differences among the percentage values, Tukey’s 
W was used to find which pairs of percentages were 
different. In short, the percentage release from the 
preparation with 130 mg/mL fibrinogen exceeded that of 110 
mg/mL fibrinogen preparation at times 1 min, 2 min and 4 
min.  In addition the percentage release from the 
preparation with 120 mg/mL fibrinogen was greater that of 
110 mg/mL fibrinogen at those times.  At 8 min and 16 min, 
the percentage release from the 110 mg/mL was significantly 
greater than from the 130 mg/mL.  At 32 min, the release 
from 120 mg/mL exceeded 130 mg/mL.  There were no 
significant differences in percentage release after 32 min.
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Table 9 : P – values for ANOVA and Tukey’s W for percentage release of 
samples with 5 % tetracycline loading (1 min to 128 min) 
Time 
Difference 
among samples 
(ANOVA) 
Pairwise Differences (Tukey’s W) 
1 min Yes, P < 0.001 130 mg/mL > 110 mg/mL (P < 0.001) 120 mg/mL > 110 mg/mL (P < 0.001) 
2 min Yes, P < 0.001 
130 mg/mL > 110 mg/mL (P < 0.001) 
120 mg/mL > 130 mg/mL (P = 0.050) 
120 mg/mL > 110 mg/mL (P < 0.001) 
4 min Yes, P = 0.001 130 mg/mL > 110 mg/mL (P < 0.001) 120 mg/mL > 110 mg/mL (P < 0.001) 
8 min Yes, P = 0.004 110 mg/mL > 130 mg/mL (P = 0.003) 
16 min Yes, P = 0.002 110 mg/mL > 130 mg/mL (P = 0.002) 
32 min Yes, P = 0.002 120 mg/mL > 130 mg/mL (P = 0.050) 
64 min None None 
128 min None None 
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Release from 10% Tetracycline Preparations 
Concentration 
 
Figure 23 : Concentration versus time for preparations with 10% 
Tetracycline (1 min to 128 min) 
 
Figure 23 shows the change in tetracycline 
concentration in the release solution over time for samples 
with 10% tetracycline loading.  Three different fibrinogen 
concentrations are shown.  Analysis of variance of the 
tetracycline concentrations at each time point showed 
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significant difference among the three fibrinogen 
concentrations (all P < 0.001).  Tukey’s W found 
significance differences between pairs of concentrations at 
all times.  These results are summarized in Table 10.  In 
summary, the 120 mg/mL fibrinogen preparations exhibited 
significantly greater release at all times.  In addition, 
at all times other than 2 min and 4 min, the 110 mg/mL 
fibrinogen preparations exhibited greater release than the 
130 mg/mL preparations. 
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Table 10 : P – values for ANOVA and Tukey’s W for release concentration 
of samples with 10 % tetracycline loading (1 min to 128 min) 
Time 
Difference 
among samples 
(ANOVA) 
Pairwise Differences (Tukey’s W) 
1 min Yes, P < 0.001 
120 mg/mL > 130 mg/mL (P < 0.001) 
120 mg/mL > 110 mg/mL (P < 0.001) 
110 mg/mL > 130 mg/mL (P = 0.001) 
2 min Yes, P < 0.001 120 mg/mL > 110 mg/mL (P < 0.001) 120 mg/mL > 130 mg/mL (P < 0.001) 
4 min Yes, P < 0.001 120 mg/mL > 110 mg/mL (P < 0.001) 120 mg/mL > 130 mg/mL (P < 0.001) 
8 min Yes, P < 0.001 
120 mg/mL > 130 mg/mL (P < 0.001) 
120 mg/mL > 110 mg/mL (P < 0.001) 
110 mg/mL > 130 mg/mL (P = 0.001) 
16 min Yes, P < 0.001 
120 mg/mL > 130 mg/mL (P < 0.001) 
120 mg/mL > 110 mg/mL (P < 0.001) 
110 mg/mL > 130 mg/mL (P < 0.001) 
32 min Yes, P < 0.001 
120 mg/mL > 130 mg/mL (P < 0.001) 
120 mg/mL > 110 mg/mL (P < 0.001) 
110 mg/mL > 130 mg/mL (P < 0.001) 
64 min Yes, P < 0.001 
120 mg/mL > 130 mg/mL (P < 0.001) 
120 mg/mL > 110 mg/mL (P < 0.001) 
110 mg/mL > 130 mg/mL (P < 0.001) 
128 min Yes, P < 0.001 
120 mg/mL > 130 mg/mL (P < 0.001) 
120 mg/mL > 110 mg/mL (P < 0.001) 
110 mg/mL > 130 mg/mL (P < 0.001) 
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Release from 10% Tetracycline Preparations 
Percentage Release 
 
Figure 24 : Percentage released versus time for preparations with 10% 
tetracycline (1 min to 128 min) 
 
Figure 24 shows the percentage release over time from 
preparations with 10% tetracycline loading for three 
different fibrinogen concentrations.  These percentage 
release profiles are identical in shape to the 
concentration profiles of Figure 23.  The concentrations 
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have been converted to percentage of tetracycline released 
by using the average mass of the sample, and the 
concentrations of Figure 23 as indicated in the Methods.  
The calculation of percentage release serves as a 
normalized view of release, independent of mass, and, 
therefore allows for a better comparison of release from 
different preparations.  
 Analysis of variance at each time event indicated that 
at all times other than 64 min and 128 min, there existed 
significant difference among the samples.  These results 
are provided below in Table 11.  At time points where ANOVA 
indicated differences among the percentage values, Tukey’s 
W was used to find which pairs of percentages were 
different. In short, the percentage release from the 
preparation with 120 mg/mL fibrinogen exceeded that of 110 
mg/mL and 130 mg/mL fibrinogen preparation at times 1 min 
and 2 min.  At 8 min and beyond, the percentage releases 
from the 110 mg/mL and 120 mg/mL were significantly greater 
than from the 130 mg/mL, but not significantly different 
from each other.  There were no significant differences in 
percentage release at 4 min. 
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Time 
Difference 
among samples 
(ANOVA) 
Pairwise Differences (Tukey’s W) 
1 min Yes, P = 0.007 120 mg/mL > 130 mg/mL (P = 0.009) 120 mg/mL > 110 mg/mL (P = 0.025) 
2 min Yes, P < 0.001 120 mg/mL > 110 mg/mL (P < 0.001) 120 mg/mL > 130 mg/mL (P = 0.008) 
4 min None None 
8 min Yes, P = 0.002 120 mg/mL > 130 mg/mL (P = 0.005) 110 mg/mL > 130 mg/mL (P = 0.007) 
16 min Yes, P < 0.001 120 mg/mL > 130 mg/mL (P = 0.001) 110 mg/mL > 130 mg/mL (P = 0.014) 
32 min Yes, P < 0.001 120 mg/mL > 130 mg/mL (P < 0.001) 110 mg/mL > 130 mg/mL (P = 0.004) 
64 min Yes, P < 0.001 120 mg/mL > 130 mg/mL (P < 0.001) 110 mg/mL > 130 mg/mL (P < 0.001) 
128 min Yes, P < 0.001 120 mg/mL > 130 mg/mL (P < 0.001) 110 mg/mL > 130 mg/mL (P < 0.001) 
 
Table 11 : P – values for ANOVA and Tukey’s W for percentage release of 
samples with 10% tetracycline loading (1 min to 128 min) 
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Long Term Release 
 
The data for long term release (1 hr to 168 hr) 
follows for all preparations.  As with the short term 
release, there exist three fibrinogen concentrations (110 
mg/mL, 120 mg/mL, and 130 mg/mL), each with three different 
loading percentages of tetracycline (2.5% w/w, 5% w/w, 10% 
w/w).  First any differences in release profiles for 
different tetracycline loading of a given fibrinogen 
concentration are reported.  Then, concentration over the 
time course of the release run (1 hr to 168 hr) is analyzed 
to determine when significant release occurred.  Then the 
results are grouped by tetracycline loading to observe the 
effects of varying fibrinogen concentrations.  All analyses 
will utilize ANOVA and Tukey’s W, with the a priori 
significance level of α = 0.05.   
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Concentration Results (Long Term) 
 
All Preparations 
 
 
Figure 25 : Concentrations of all preparations over time 168 hours 
 
 Figure 25 shows release solution concentrations of all 
preparations over time 168 hours.  The error bars have been 
omitted for clarity.  The general trend shows that 
concentrations at time events increase with increasing 
tetracycline loading, and decrease with increasing 
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fibrinogen concentration (fiber diameter).  However, the 
statistics only validate one of these assertions.  ANOVA 
observed differences among concentrations at all times (all 
P < 0.05) – however, Tukey’s W only showed significant 
differences between concentration values of pairs that were 
of different tetracycline concentrations.  For example, two 
preparations of identical tetracycline loading (110 mg/mL 
with 5% tetracycline and 120 mg/mL with 5% tetracycline) 
would not have significantly different concentrations in 
their release solutions at any particular time point in the 
run.  Significant differences were only seen when the 
tetracycline weight percentages differed.  Tables replete 
with P-values of these comparisons can be found in the 
Appendix.  Individual figures for each fibrinogen 
concentration and each tetracycline percentage follow. 
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Release from 110 mg/mL Fibrinogen 
Concentration 
 
Figure 26 : Concentration versus time 110 mg/mL fibrinogen with 
tetracycline hydrochloride (1 hr to 168 hr) 
 
Figure 26 shows the change in tetracycline 
concentration in the release solution over time for 110 
mg/mL fibrinogen samples.  Three different loading 
percentages of tetracycline are shown.  Analysis of 
variance of the tetracycline concentrations at each time 
point showed significant difference among the three 
tetracycline loading concentrations (all P < 0.001).  
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Tukey’s W found that, for each time point, the release 
concentration of the 10% preparation was significantly 
higher than the 5% preparation (all P < 0.001), and that 
the release concentration of the 5% preparation was higher 
than that of the 2.5% preparation (all P < 0.001).  
Therefore, the three profiles in Figure 26 are 
significantly different. 
  For the 110 mg/mL fibrinogen with 2.5% tetracycline, 
ANOVA revealed that the concentrations from 1 hr to 168 hr 
were not significantly different.  This indicates no 
significant release during the duration of this run (no 
release after 1 hour). 
For the 110 mg/mL fibrinogen with 5% tetracycline, 
ANOVA revealed that the concentrations from 1 min to 128 
min were significantly different (P < 0.001).  However, 
Tukey’s W found that the only significant differences in 
concentration were observed between 1 hour and all times 
greater than 24 hours.  Since no concentrations after 24 
hours were judged significantly different from the 24 
value, no significant release can be reported after 24 
hours. (See Table 29 in Appendix for all pairwise P-values) 
For the 110 mg/mL fibrinogen with 10% tetracycline, 
ANOVA revealed that the concentrations from 1 hr to 168 hr 
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were not significantly different.  This indicates no 
significant release during the duration of this run (no 
release after 1 hour).
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Release from 110 mg/mL Fibrinogen 
Percentage Release 
 
Figure 27 : Percentage released versus time for 110 mg/mL fibrinogen 
with tetracycline hydrochloride (1 hr to 168 hr) 
 
Figure 27 shows the percentage release over time from 
preparations of 110 mg/mL fibrinogen with three different 
tetracycline loading concentrations.  These percentage 
release profiles are identical in shape to the 
concentration profiles of Figure 26.  The concentrations 
have been converted to percentage of tetracycline released 
by using the average mass of the sample, and the 
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concentrations of Figure 26 as indicated in the Methods.  
The calculation of percentage release serves as a 
normalized view of release, independent of mass, and, 
therefore allows for a better comparison of release from 
different preparations.  
 Analysis of variance at each time event indicated that 
at only time point 1 hour, there existed significant 
difference among the samples.  These results are provided 
below in Table 12.  At time points where ANOVA indicated 
differences among the percentage values, Tukey’s W was used 
to find which pairs of percentages were different. These 
results are also provided in Table 12.  The percentage 
release between 110 mg/mL preparations of different 
tetracycline loadings differed only at 1 hour.  At 1 hour, 
the 2.5% tetracycline and 10 % tetracycline preparations 
exhibited greater release than the 5% tetracycline 
preparation. 
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Time 
Difference 
among samples 
(ANOVA) 
Pairwise Differences   
(Tukey’s W) 
1 hr Yes, P < 0.001 2.5% > 5% (P < 0.001) 10% > 5% (P < 0.001) 
4 hr None None 
14 hr None None 
24 hr None None 
48 hr None None 
72 hr None None 
120 hr None None 
168 hr None None  
 
Table 12 : P – values for ANOVA and Tukey’s W for 110 mg/mL samples of 
different tetracycline loading (1 min to 128 min)  
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Release from 120 mg/mL Fibrinogen 
Concentration 
 
Figure 28 : Concentration versus time 120 mg/mL fibrinogen with 
tetracycline hydrochloride (1 hr to 168 hr) 
 
Figure 28 shows the change in tetracycline 
concentration in the release solution over time for 120 
mg/mL fibrinogen samples.  Three different loading 
percentages of tetracycline are shown.  Analysis of 
variance of the tetracycline concentrations at each time 
point showed significant difference among the three 
tetracycline loading concentrations (all P < 0.001).  
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0.16
0 50 100 150 200
Time (hours)
Co
nc
en
tr
at
io
n 
(m
g/
mL
)
120 w/ 2.5% 120 w/ 5% 120 w/ 10%
99 
 
Tukey’s W found that, for each time point, the release 
concentration of the 10% preparation was significantly 
higher than the 5% preparation (all P < 0.001), and that 
the release concentration of the 5% preparation was higher 
than that of the 2.5% preparation (all P < 0.001).  
Therefore, the three profiles in Figure 28 are 
significantly different. 
 For the 120 mg/mL fibrinogen with 2.5% tetracycline, 
ANOVA revealed that the concentrations from 1 hr to 168 hr 
were significantly different (P = 0.035).  However, Tukey’s 
W returned no significant differences between any values. 
This indicates no significant release can be inferred over 
the duration of this run (no release after 1 hour). 
For the 120 mg/mL fibrinogen with 5% tetracycline, 
ANOVA revealed that the concentrations from 1 min to 128 
min were significantly different (P < 0.001).  However, 
Tukey’s W found that the only significant differences in 
concentration were observed between 48 hours and 1 hour.  
Since no concentrations after 48 hours were judged 
significantly different from the 48 hour value, no 
significant release can be reported after 48 hours. (See 
Table 30 in Appendix for all pairwise P-values) 
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 For the 120 mg/mL fibrinogen with 10% tetracycline, 
ANOVA revealed that the concentrations from 1 hr to 168 hr 
were significantly different (P = 0.031).  However, Tukey’s 
W returned no significant differences between any values. 
This indicates no significant release can be inferred over 
the duration of this run (no release after 1 hour).
101 
 
Release from 120 mg/mL Fibrinogen 
Percentage Release 
 
Figure 29 : Percentage released versus time for 120 mg/mL fibrinogen 
with tetracycline hydrochloride (1 hr to 168 hr) 
 
Figure 29 shows the percentage release over time from 
preparations of 120 mg/mL fibrinogen with three different 
tetracycline loading concentrations.  These percentage 
release profiles are identical in shape to the 
concentration profiles of Figure 28.  The concentrations 
have been converted to percentage of tetracycline released 
by using the average mass of the sample, and the 
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concentrations of Figure 28 as indicated in the Methods.  
The calculation of percentage release serves as a 
normalized view of release, independent of mass, and, 
therefore allows for a better comparison of release from 
different preparations.  
 Analysis of variance at each time event indicated that 
at no time points did there exist significant differences 
among the samples.  Therefore, all 120 mg/mL fibrinogen 
preparations exhibited similar percentage release. 
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Release from 130 mg/mL Fibrinogen 
Concentration 
 
 
Figure 30 : Concentration versus time 130 mg/mL fibrinogen with 
tetracycline hydrochloride (1 hr to 168 hr) 
 
Figure 30 shows the change in tetracycline 
concentration in the release solution over time for 130 
mg/mL fibrinogen samples.  Three different loading 
percentages of tetracycline are shown.  Analysis of 
variance of the tetracycline concentrations at each time 
point showed significant difference among the three 
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tetracycline loading concentrations (all P < 0.001).  
Tukey’s W found that, for each time point, the release 
concentration of the 10% preparation was significantly 
higher than the 5% preparation (all P < 0.001), and that 
the release concentration of the 5% preparation was higher 
than that of the 2.5% preparation (all P < 0.001).  
Therefore, the three profiles in Figure 30 are 
significantly different. 
 For the 130 mg/mL fibrinogen with 2.5% tetracycline, 
ANOVA revealed that the concentrations from 1 hr to 168 hr 
were significantly different (P = 0.045).  However, Tukey’s 
W returned no significant differences between any values. 
This indicates no significant release can be inferred over 
the duration of this run (no release after 1 hour). 
For the 130 mg/mL fibrinogen with 5% tetracycline, 
ANOVA revealed that the concentrations from 1 min to 128 
min were significantly different (P < 0.001).  However, 
Tukey’s W found that the only significant differences in 
concentration were observed between times after 24 hours 
and 1 hour.  Since no concentrations after 24 hours were 
judged significantly different from the 24 hour value, no 
significant release can be reported after 24 hours. (See 
Table 30 in Appendix for all pairwise P-values) 
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 For the 130 mg/mL fibrinogen with 10% tetracycline, 
ANOVA revealed that the concentrations from 1 hr to 168 hr 
were significantly different (P = 0.031).  This indicates 
no significant release can be inferred over the duration of 
this run (no release after 1 hour).
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Release from 130 mg/mL Fibrinogen 
Percentage Release 
 
Figure 31 : Percentage released versus time for 130 mg/mL fibrinogen 
with tetracycline hydrochloride (1 hr to 168 hr) 
 
Figure 31 shows the percentage release over time from 
preparations of 130 mg/mL fibrinogen with three different 
tetracycline loading concentrations.  These percentage 
release profiles are identical in shape to the 
concentration graphs of Figure 30.  The concentrations have 
been converted to percentage of tetracycline released by 
using the average mass of the sample, and the 
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concentrations of Figure 30 as indicated in the Methods.  
The calculation of percentage release serves as a 
normalized view of release, independent of mass, and, 
therefore allows for a better comparison of release from 
different preparations.  
 Analysis of variance at each time event indicated that 
at no time points did there exist significant differences 
among the samples.  Therefore, all 130 mg/mL fibrinogen 
preparations exhibited similar percentage release. 
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Long Term Release 
 
Release from 2.5% Tetracycline Preparations 
 
Concentration 
 
Figure 32 : Concentration versus time for preparations with 2.5% 
tetracycline over 168 hours 
 
Figure 32 shows the tetracycline concentration of the 
release solution over time 168 hours for fibrinogen 
preparations with 2.5% tetracycline loading.  Three 
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different fibrinogen concentrations are shown.  Analysis of 
variance of the tetracycline concentrations at each time 
point showed significant difference among the three 
fibrinogen concentrations at all times other than 4 hours 
(all P < 0.05).  Tukey’s W found significance differences 
between pairs of concentrations at all times other than 4 
hours.  These results are summarized in Table 13.  In 
summary, the 120 mg/mL fibrinogen preparations exhibited 
significantly greater release than 130 mg/mL fibrinogen at 
all times other than 4 hours.  In addition, at 14 hours, 
the 120 mg/mL fibrinogen preparation expressed significant 
greater release than the 110 mg/mL preparation.  Also, at 1 
hour, 24 hours, and 48 hours, the 110 mg/mL fibrinogen 
preparation expressed significantly higher release than the 
130 mg/mL preparations. 
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Table 13 : P – values for ANOVA and Tukey’s W for release concentration 
of samples with 2.5 % tetracycline loading (1 hr to 168 hr) 
Time 
Difference 
among samples 
(ANOVA) 
Pairwise Differences (Tukey’s W) 
1 hr Yes, P < 0.001 120 mg/mL > 130 mg/mL (P = 0.005) 110 mg/mL > 130 mg/mL (P < 0.001) 
4 hr None None 
14 hr Yes, P = 0.002 120 mg/mL > 110 mg/mL (P = 0.003) 120 mg/mL > 130 mg/mL (P = 0.013) 
24 hr Yes, P < 0.001 120 mg/mL > 130 mg/mL (P < 0.001) 110 mg/mL > 130 mg/mL (P = 0.008) 
48 hr Yes, P < 0.001 120 mg/mL > 130 mg/mL (P < 0.001) 110 mg/mL > 130 mg/mL (P = 0.013) 
72 hr Yes, P = 0.006 120 mg/mL > 130 mg/mL (P = 0.005) 
120 hr Yes, P = 0.023 120 mg/mL > 130 mg/mL (P = 0.034) 
168 hr Yes, P = 0.008 120 mg/mL > 130 mg/mL (P = 0.008) 
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Release from 2.5% Tetracycline Preparations 
 
Percentage Release 
 
 
Figure 33 : Percentage release versus time for preparations with 2.5% 
tetracycline over 168 hours 
Figure 33 shows the percentage release over time from 
preparations with 2.5% tetracycline loading for three 
different fibrinogen concentrations.  These percentage 
release profiles are identical in shape to the 
concentration graphs of Figure 32.  The concentrations have 
been converted to percentage of tetracycline released by 
using the average mass of the sample, and the 
concentrations of Figure 32 as indicated in the Methods.  
0
5
10
15
20
25
30
35
40
0 20 40 60 80 100 120 140 160 180
Time (hours)
Pe
rc
en
ta
ge
 R
el
ea
se
d
110 w/ 2.5% 120 w/ 2.5% 130 w/ 2.5%
112 
 
The calculation of percentage release serves as a 
normalized view of release, independent of mass, and, 
therefore allows for a better comparison of release from 
different preparations.  
 Analysis of variance at each time event indicated that 
at times 1 hour, 14 hours, 24 hours, and 48 hours, there 
existed significant difference among the samples.  These 
results are provided below in Table 14.  At time points 
where ANOVA indicated differences among the percentage 
values, Tukey’s W was used to find which pairs of 
percentages were different.  In short, significant 
differences in percentage released were seen at 1 hour, 14 
hours, 24 hours, and 48 hours.  At each of these times, the 
110 mg/mL preparations exhibited higher release than the 
130 mg/mL preparations.  In addition, at time 1 hour, the 
110 mg/mL preparations had significantly higher release 
than the 120 mg/mL preparations.  No other significant 
differences were found. 
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Table 14 : P – values for ANOVA and Tukey’s W for percentage release of 
samples with 2.5 % tetracycline loading (1 hr to 168 hr) 
Time 
Difference 
among samples 
(ANOVA) 
Pairwise Differences (Tukey’s W) 
1 hr Yes, P < 0.001 110 mg/mL > 120 mg/mL (P = 0.003) 110 mg/mL > 130 mg/mL (P < 0.001) 
4 hr None None 
14 hr Yes, P = 0.017 110 mg/mL > 130 mg/mL (P = 0.013) 
24 hr Yes, P = 0.018 110 mg/mL > 130 mg/mL (P = 0.013) 
48 hr Yes, P = 0.028 110 mg/mL > 130 mg/mL (P = 0.022) 
72 hr None None 
120 hr None None 
168 hr None None 
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Concentration Results (Long Term) 
Release from 5% Tetracycline Preparations 
 
Concentration 
 
Figure 34 : Concentration versus time for preparations with 5% 
tetracycline over 168 hours 
 
Figure 34 shows the tetracycline concentration of the 
release solution over time 168 hours for fibrinogen 
preparations with 5% tetracycline loading.  Three different 
fibrinogen concentrations are shown.  Analysis of variance 
of the tetracycline concentrations at each time point 
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showed significant difference among the three fibrinogen 
concentrations at all times (all P < 0.05).  Tukey’s W 
found significance differences between pairs of 
concentrations at all times.  These results are summarized 
in Table 15.  In summary, the 110 mg/mL fibrinogen 
preparations exhibited significantly greater release than 
130 mg/mL fibrinogen at all times.  In addition, at all 
times other than 4 hours, the 120 mg/mL fibrinogen 
preparations expressed significant greater release than the 
130 mg/mL preparations.  Also, at 120 hours and 168 hours, 
the 110 mg/mL fibrinogen preparation expressed 
significantly higher release than the 120 mg/mL 
preparations. 
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Table 15 : P – values for ANOVA and Tukey’s W for release concentration 
of samples with 5 % tetracycline loading (1 hr to 168 hr) 
 
Time 
Difference 
among samples 
(ANOVA) 
Pairwise Differences (Tukey’s W) 
1 hr Yes, P = 0.008 120 mg/mL > 130 mg/mL (P = 0.042) 110 mg/mL > 130 mg/mL (P = 0.008) 
4 hr Yes, P = 0.004 110 mg/mL > 130 mg/mL (P = 0.003) 
14 hr Yes, P < 0.001 120 mg/mL > 130 mg/mL (P = 0.018) 110 mg/mL > 130 mg/mL (P < 0.001) 
24 hr Yes, P < 0.001 120 mg/mL > 130 mg/mL (P = 0.015) 110 mg/mL > 130 mg/mL (P < 0.001) 
48 hr Yes, P < 0.001 120 mg/mL > 130 mg/mL (P = 0.005) 110 mg/mL > 130 mg/mL (P < 0.001) 
72 hr Yes, P = 0.003 120 mg/mL > 130 mg/mL (P = 0.044) 110 mg/mL > 130 mg/mL (P = 0.002) 
120 hr Yes, P < 0.001 
120 mg/mL > 130 mg/mL (P < 0.001) 
110 mg/mL > 120 mg/mL (P = 0.008) 
110 mg/mL > 130 mg/mL (P < 0.001) 
168 hr Yes, P < 0.001 
120 mg/mL > 130 mg/mL (P = 0.002) 
110 mg/mL > 120 mg/mL (P < 0.001) 
110 mg/mL > 130 mg/mL (P < 0.001) 
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Release from 5% Tetracycline Preparations 
 
Percentage Release 
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Figure 35: Percentage release versus time for preparations with 5% 
tetracycline over 168 hours 
 
Figure 35 shows the percentage release over time from 
preparations with 5% tetracycline loading for three 
different fibrinogen concentrations.  These percentage 
release profiles are identical in shape to the 
concentration profiles of Figure 34.  The concentrations 
have been converted to percentage of tetracycline released 
by using the average mass of the sample, and the 
concentrations of Figure 34 as indicated in the Methods.  
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The calculation of percentage release serves as a 
normalized view of release, independent of mass, and, 
therefore allows for a better comparison of release from 
different preparations.  
 Analysis of variance at each time event indicated that 
there existed significant difference among the samples at 
all times.  These results are provided below in Table 16.  
At time points where ANOVA indicated differences among the 
percentage values, Tukey’s W was used to find which pairs 
of percentages were different.  In short, significant 
differences in percentage released were seen at all times.  
At each of these times, the 110 mg/mL preparations 
exhibited higher release than the 130 mg/mL preparations.  
In addition, at time 4 hours, 120 hours, and 168 hours the 
110 mg/mL preparations had significantly higher release 
than the 120 mg/mL preparations.  Also, at times 48 hours, 
120 hours, and 168 hours, the 120 mg/mL preparations had 
significantly greater release than the 130 mg/mL 
preparations. 
 
 
119 
 
 
Table 16: P – values for ANOVA and Tukey’s W for percentage release of 
samples with 5 % tetracycline loading (1 hr to 168 hr) 
 
Time 
Difference 
among samples 
(ANOVA) 
Pairwise Differences (Tukey’s W) 
1 hr Yes, P = 0.012 110 mg/mL > 130 mg/mL (P = 0.009) 
4 hr Yes, P = 0.004 110 mg/mL > 120 mg/mL (P = 0.004) 110 mg/mL > 130 mg/mL (P = 0.030) 
14 hr Yes, P = 0.001 110 mg/mL > 130 mg/mL (P < 0.001) 
24 hr Yes, P < 0.001 110 mg/mL > 130 mg/mL (P < 0.001) 
48 hr Yes, P < 0.001 110 mg/mL > 130 mg/mL (P < 0.001) 120 mg/mL > 130 mg/mL (P = 0.021) 
72 hr Yes, P = 0.004 110 mg/mL > 130 mg/mL (P = 0.003) 
120 hr Yes, P < 0.001 
110 mg/mL > 130 mg/mL (P < 0.001) 
110 mg/mL > 120 mg/mL (P < 0.001) 
120 mg/mL > 130 mg/mL (P = 0.010) 
168 hr Yes, P < 0.001 
110 mg/mL > 130 mg/mL (P < 0.001) 
110 mg/mL > 120 mg/mL (P < 0.001) 
120 mg/mL > 130 mg/mL (P = 0.022) 
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Release from 10% Tetracycline Preparations 
 
Concentration 
 
 
Figure 36 : Concentration versus time for preparations with 10% 
tetracycline over 168 hours 
 
Figure 36 shows the tetracycline concentration of the 
release solution over time 168 hours for fibrinogen 
preparations with 10% tetracycline loading.  Three 
different fibrinogen concentrations are shown.  Analysis of 
variance of the tetracycline concentrations at each time 
point showed significant difference among the three 
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fibrinogen concentrations at all times (all P < 0.05).  
Tukey’s W found significance differences between pairs of 
concentrations at all times.  These results are summarized 
in Table 17.  In summary, there is a significant trend 
across all times.  At all times except 72 hours, the 110 
mg/mL preparations exhibited significantly higher release 
than the 120 mg/mL preparations, and the 120 mg/ml 
preparations exhibited significantly higher release than 
the 130 mg/mL preparations.  At 72 hours, the release from 
110 mg/mL and 120 mg/mL were not significantly different, 
but were both significantly higher than that of the 130 
mg/mL preparations. 
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Table 17 : P – values for ANOVA and Tukey’s W for release concentration 
of samples with 10 % tetracycline loading (1 hr to 168 hr) 
 
Time 
Difference 
among samples 
(ANOVA) 
Pairwise Differences (Tukey’s W) 
1 hr Yes, P < 0.001 
120 mg/mL > 130 mg/mL (P < 0.001) 
110 mg/mL > 120 mg/mL (P < 0.001) 
110 mg/mL > 130 mg/mL (P < 0.001) 
4 hr Yes, P < 0.001 
120 mg/mL > 130 mg/mL (P = 0.010) 
110 mg/mL > 120 mg/mL (P < 0.001) 
110 mg/mL > 130 mg/mL (P < 0.001) 
14 hr Yes, P < 0.001 
120 mg/mL > 130 mg/mL (P = 0.015) 
110 mg/mL > 120 mg/mL (P = 0.007) 
110 mg/mL > 130 mg/mL (P < 0.001) 
24 hr Yes, P < 0.001 
120 mg/mL > 130 mg/mL (P = 0.006) 
110 mg/mL > 120 mg/mL (P = 0.029) 
110 mg/mL > 130 mg/mL (P < 0.001) 
48 hr Yes, P < 0.001 
120 mg/mL > 130 mg/mL (P < 0.001) 
110 mg/mL > 120 mg/mL (P = 0.008) 
110 mg/mL > 130 mg/mL (P < 0.001) 
72 hr Yes, P < 0.001 120 mg/mL > 130 mg/mL (P = 0.035) 110 mg/mL > 130 mg/mL (P < 0.001) 
120 hr Yes, P < 0.001 
120 mg/mL > 130 mg/mL (P = 0.021) 
110 mg/mL > 120 mg/mL (P = 0.014) 
110 mg/mL > 130 mg/mL (P < 0.001) 
168 hr Yes, P < 0.001 
120 mg/mL > 130 mg/mL (P = 0.009) 
110 mg/mL > 120 mg/mL (P = 0.003) 
110 mg/mL > 130 mg/mL (P < 0.001) 
123 
 
Release from 10% Tetracycline Preparations 
 
Percentage Release 
 
 
Figure 37: Percentage release versus time for preparations with 10% 
tetracycline over 168 hours 
 
Figure 37 shows the percentage release over time from 
preparations with 10% tetracycline loading for three 
different fibrinogen concentrations.  These percentage 
release profiles are identical in shape to the 
concentration profiles of Figure 36.  The concentrations 
have been converted to percentage of tetracycline released 
by using the average mass of the sample, and the 
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concentrations of Figure 36 as indicated in the Methods.  
The calculation of percentage release serves as a 
normalized view of release, independent of mass, and, 
therefore allows for a better comparison of release from 
different preparations.  
 Analysis of variance at each time event indicated that 
there existed significant difference among the samples at 
all times.  These results are provided below in Table 18.  
At time points where ANOVA indicated differences among the 
percentage values, Tukey’s W was used to find which pairs 
of percentages were different.  In short, significant 
differences in percentage released were seen at all times.  
At each of these times, the 110 mg/mL preparations 
exhibited higher release than the 130 mg/mL preparations.  
In addition, at time 1 hour, 4 hours, 14 hours, and 168 
hours the 110 mg/mL preparations had significantly higher 
release than the 120 mg/mL preparations.  Also, at times 4 
hours, 24 hours, and 48 hours, the 120 mg/mL preparations 
had significantly greater release than the 130 mg/mL 
preparations. 
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Table 18: P – values for ANOVA and Tukey’s W for percentage release of 
samples with 10 % tetracycline loading (1 hr to 168 hr) 
 
Time 
Difference 
among samples 
(ANOVA) 
Pairwise Differences (Tukey’s W) 
1 hr Yes, P < 0.001 
110 mg/mL > 130 mg/mL (P < 0.001) 
110 mg/mL > 120 mg/mL (P < 0.001) 
120 mg/mL > 130 mg/mL (P < 0.001) 
4 hr Yes, P < 0.001 110 mg/mL > 130 mg/mL (P < 0.001) 110 mg/mL > 120 mg/mL (P = 0.003) 
14 hr Yes, P < 0.001 110 mg/mL > 130 mg/mL (P < 0.001) 110 mg/mL > 120 mg/mL (P = 0.043) 
24 hr Yes, P < 0.001 110 mg/mL > 130 mg/mL (P < 0.001) 120 mg/mL > 130 mg/mL (P = 0.040) 
48 hr Yes, P < 0.001 110 mg/mL > 130 mg/mL (P < 0.001) 120 mg/mL > 130 mg/mL (P = 0.013) 
72 hr Yes, P = 0.004 110 mg/mL > 130 mg/mL (P = 0.003) 
120 hr Yes, P < 0.001 110 mg/mL > 130 mg/mL (P < 0.001) 
168 hr Yes, P < 0.001 110 mg/mL > 130 mg/mL (P < 0.001) 110 mg/mL > 120 mg/mL (P = 0.021) 
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Figure 38 : Percentage Release over time for all preparations (error 
bars excluded for clarity) 
 
 Figure 38 presents percentage release data for all 
preparations over the long term 168 hour release study.  
Error bars have been submitted for clarity.  The graph 
suggests several trends.  First, preparations of the same 
fibrinogen concentrations are grouped closely and exhibit 
similar release.  Secondly, upon viewing these fibrinogen 
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concentrations, those preparations of lower fibrinogen 
concentration tend to release a greater percentage of 
tetracycline over time (110 mg/mL higher than 120 mg/mL, 
120 mg/mL higher than 130 mg/mL).  Lastly, the ultimate 
percentage released for all preparations is roughly 20% to 
30%.   
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Percentage Release Statistics 
 
 Analyses of variance were performed at each time value 
for the percentage release of all preparations.  All showed 
significant difference among the preparations.  However, 
with two noted exceptions, Tukey’s W only showed pairwise 
differences between preparations of fibrinogen 
concentration 110 mg/mL and those of 120 mg/mL or 130 mg/mL 
fibrinogen.  These differences were not found in every 
comparison, but with 36 pairwise comparisons for each time 
event, and relatively few significant differences, 
individual statements of release differences would be 
expansive.  A summary of these differences are listed in 
the Appendix.  The exceptions to the above trend occurred 
at 1 hour (110 w/ 10% > 110 w/ 5%) and 48 hours (120 w/ 5% 
> 130 w/ 10% and 120 w/ 2.5% > 130 w/ 10%).  The data for 
percentage release by fibrinogen concentration and by 
tetracycline loading was offered separately in earlier 
sections.  This analysis is supplied only to offer a more 
global perspective. 
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Discussion 
 
 
Fiber Diameter and Pore Area 
 As shown in the results, the addition of tetracycline 
in weight percentages of up to 10% has no significant 
effect on fiber diameter.  Fiber diameter of electrospun 
fibrinogen has been shown to be a function of solution 
concentration and these results demonstrate this as well7.  
In addition, tetracycline had no significant effect on pore 
area, as this is often controlled by fiber diameter. 
 
Mechanical Data 
 Regardless of the mechanical property measured, the 
addition of tetracycline showed no significant effect.  The 
modulus of dry samples was dependent on the original 
fibrinogen concentration, with higher fibrinogen 
concentrations in the electrospinning solution yielding 
electrospun mats with stiffer moduli.  This is probably due 
to the increase in fiber diameter of the resulting mats 
(see fiber diameter data).  The testing of modulus for wet 
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preparation showed a similar trend, with differences 
between the 110 mg/mL and 120 mg/mL and between 110 mg/mL 
and 130 mg/mL being significant.  In each case, the greater 
fibrinogen concentration yielded a higher modulus. A 
greater sample size may have allowed for more significance 
to be seen between 120 mg/mL and 130 mg/mL.  The modulus of 
wet fibrinogen was consistently seen as lower than that of 
the dry preparation. 
There was no significant difference among preparations 
in breaking strain.  Although there may appear to be a 
trend of increasing breaking strain with increasing 
fibrinogen concentration (and fiber diameter), the 
variation among samples and the incongruities within 
electrospun fibrinogen may have occluded any possible 
statistically significant differences.  Wet breaking strain 
did exhibit a trend, with increasing fibrinogen 
concentration causing an increasing in the strain to break.  
The significant difference between 110 mg/mL and 120 mg/mL 
and 110 mg/mL and 130 mg/mL lend evidence to the dependence 
between breaking strain and fibrinogen concentration.  An 
amazing property of fibrinogen is demonstrated in the 
possible ten fold increase in breaking strain when 
fibrinogen mats are hydrated.  Although the modulus 
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decreases with hydration, the material becomes ultimately 
more flexible. 
 The peak stresses of dry preparations were 
statistically different, and the 130 mg/mL preparations 
were statistically greater than the 110 mg/mL preparations.  
A similar result was found in the hydrated preparations, 
with significantly higher peak stresses in the 120 mg/mL 
and 130 mg/mL preparations, as compared to the 110 mg/mL.  
 Since the addition of tetracycline had little effect 
on the mechanical properties, it can be inferred that the 
fibrinogen concentration has a great effect upon the 
mechanical properties, for it has a large contribution to 
fiber diameter.  A larger diameter fiber will be stronger 
in tension and should increase modulus, peak stress, and 
breaking strain of materials.  Since all other variables of 
the fabrication process were controlled (distance to 
mandrel, spinning voltage, mandrel rotation and geometry), 
the changes in fiber diameter (and mechanical properties) 
should be able to be attributed to solution concentration. 
 The greater flexibility of hydrated fibrinogen is more 
interesting.  The hydration of fibrinogen in PBS has an 
obvious effect, increasing flexibility, but the cause is 
speculative.  If the technology had been available to 
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observe fibers in this wet state, perhaps a change in fiber 
geometry, size, or orientation could address this issue.  
The difference in wet fibrinogen may also address the 
relatively short period of release. 
 
Short Term Release 
 The effects of tetracycline loading on release can be 
easily summarized.  An increase in loading offers a higher 
concentration of tetracycline in the release solution.  
This is probably because of a greater mass of tetracycline 
on the surface of the fibrinogen, which readily dissolves 
into solution.  This increase in release concentration was 
seen in all preparations.  Upon viewing the short term 
release by tetracycline loading percentage, it was seen 
that the 120 mg/mL preparations showed greater release than 
other preparations.  This result is possibly due to some 
incongruities between samples, as the 110 mg/mL 
preparations showed higher release than larger diameter 
preparations in the long term study.  In summary, higher 
tetracycline loading percentage led to higher release 
because of increased mass of available tetracycline, and 
smaller diameter fibers (except for 120 mg/mL exceptions) 
also led to greater release.  The smaller diameter fibers 
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offer more surface area for tetracycline to exist and be 
readily dissolved. 
However, regardless of preparation, the release is 
short-lived, often reaching a plateau within minutes, with 
no significant release thereafter.  This was also seen in 
the longer term study.  With the differing mechanical 
behavior of hydrated fibrinogen, a possible explanation is 
also the swelling of fibers. 
 As the fibrinogen hydrates, the individual fibers 
could swell, and their increase in diameter could narrow 
whatever pores that were available for the tetracycline in 
the inner part of the mat to diffuse into solution.  Since 
the short term study showed that no more than 25% of the 
tetracycline in the mat entered solution, this sealing of 
pores and possible sequestration of tetracycline happens 
rapidly.  In addition, the higher release percentages seen 
from preparation of smaller fiber diameters suggests that 
smaller fibers take more time and hydration to reach the 
point where their increased size prevents further release 
from the interior of the sample. 
 This relatively low release of tetracycline could have 
another cause.  The calculation of percentage release 
requires an unsupportable assumption – that the entire 
134 
 
amount of tetracycline in the electrospinning solution is 
incorporated into the final product.  This seems 
reasonable, but could not have been verified without 
destruction of the sample.  This is a recommendation for a 
later study. 
 The “missing” tetracycline may not exist as a 
potential drawback – it could be a benefit.  If the 
tetracycline is indeed trapped within the fibrinogen, then 
the degradation of fibrinogen would lead to further 
release.  Since fibrinogen is insoluble in PBS, this was 
not observed.  However, in applications as implantable 
tissue scaffolding or wound dressing, there is a possible 
rediscovery of the tetracycline.  Upon exposure to thrombin 
in blood, the fibrinogen will be cleaved to fibrin, forming 
a clot, the “provisional matrix”.  As the tissue remodels 
this matrix, replacing it with collagen, the fibrin will be 
exposed to enzymes that degrade it.  As the fibrin is 
degraded, and the matrix replaced, any tetracycline within 
could be liberated.   
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Long Term Release 
 The long term results are similar in profiles to those 
of the short term release.  The reliance on loading 
percentages is again illustrated.  The data suggests that 
concentration is dependent on increasing loading and on 
decreasing fibrinogen concentration (fiber diameter).  
Although not judged significant at every time point, a 
decrease in fiber diameter (per concentration change), did 
offer more fiber surface area, so that the early surface 
release could be higher.   
In many of the preparations, no significant difference 
in tetracycline concentration existed between any time 
values from 1 hour and 168 hours.  Therefore, no release 
can be confirmed after 1 hour.  A purpose of the short term 
study was to show the rapid onset of concentration, and it 
is apparent that most release occurs before an hour.  There 
were samples that showed a significant change (release) up 
to 48 hours, yet the general trend was that release had a 
shorter duration.  This could also be attributed to the 
possibly swelling of the fibers. 
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Recommendations for Further Study 
 This study was not rife with weakness, but in 
retrospect, many things could have been improved.  One 
major concern is the lack of uniformity with the samples 
taken from preparations.  Although each sample had the same 
diameter, and was obtained with the same instrument, there 
were variations.  The electrospun fibrinogen mat does vary 
in thickness, so pieces with identical cross-sectional area 
would have different masses.  Using the average mass of the 
samples introduced error, as the percentage calculation was 
dependent upon mass.  If a particular sample had a mass 
quite different from the sample, the variation would be 
seen in the percentage results.  Since the release of 
tetracycline has been suggested to be restricted to the 
surface of the mat (quick cessation of release), the 
thickness of the mat is not of the same concern.  These 
problems could be remedied by the use of larger sample 
pieces for the release study. 
 Also, a fundamental change in design could address the 
above issue, but comes with a price.  This study was 
conducted with independent samples.  A given sample of a 
preparation offered data at only one time event.  A design 
with a larger sample that was repeatedly measured for 
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release would reduce variation, but this design would 
demand the replacement of harvested release solution, 
constant recalculation, and different statistics. 
 A larger sample size for all facets of the experiment 
would undoubtedly reduce variation and show more 
significance.  A less conservative ancillary to ANOVA (the 
author’s choice was Tukey’s W) might have given more 
significant results.  Human error could be lessened if the 
spectrophotometry could be accomplished without disturbing 
the sample, that is, if the absorbance could be continually 
measured while the sample releases its tetracycline. 
 Also, a method for observing the tetracycline within 
the mat would address the surface dissolution theory.  
Cross-sections of the mat could possibly be viewed with TEM 
or fluorescence microscopy to “see” where the tetracycline 
is.  Or, the enzymatic breakdown of fibrinogen mats would 
release the tetracycline that is conceivably trapped. 
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Conclusion 
 
 In summary, the presence of tetracycline has minimal 
effect on mechanical properties (modulus, peak stress, 
breaking strain) and material geometry (fiber diameter and 
pore size) of electrospun fibrinogen.  The release data 
suggests that release concentration is dependent upon 
tetracycline loading percentage (available release 
material).  The release concentration is also dependent 
upon fiber diameter, as smaller fibers allow for more 
release because of their overall increased surface area.  
The incomplete release of tetracycline from electrospun 
fibrinogen could be a result of the swelling of the fibers, 
occluding paths of release from the interior of the mat.  
This theory is supported by the higher release percentages 
of smaller diameter electrospun mats, which will undergo 
more swelling over a longer time period to reach altered 
diameters than can prevent release.  These results showed 
that tetracycline is a viable addition to applications of 
electrospun fibrinogen, and that the release of 
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tetracycline from the same can be controlled by the factors 
of fibrinogen concentration and tetracycline loading 
percentage.   
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Appendix 
 
 
Figure 39 : Standard Curve of Absorbance versus tetracycline 
concentration 
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Time(hours) Pairwise Differences with P-values 
1  
110 w/ 10% > 130 w/ 10%            (P < 0.001) 
110 w/ 10% > 130 w/ 5%             (P < 0.001) 
110 w/ 10% > 130 w/ 2.5%           (P < 0.001) 
110 w/ 10% > 120 w/ 10%            (P < 0.001) 
110 w/ 10% > 120 w/ 2.5%           (P < 0.001) 
110 w/ 10% > 120 w/ 5%             (P < 0.001) 
110 w/ 10% > 110 w/ 5%             (P = 0.044) 
110 w/ 2.5% > 130 w/ 10%           (P < 0.001) 
110 w/ 2.5% > 130 w/ 5%            (P < 0.001) 
110 w/ 2.5% > 130 w/ 2.5%          (P < 0.001) 
110 w/ 2.5% > 120 w/ 10%           (P = 0.003) 
110 w/ 2.5% > 120 w/ 5%            (P = 0.007) 
110 w/ 2.5% > 120 w/ 2.5%          (P = 0.003) 
110 w/ 5% > 130 w/ 10%             (P = 0.005) 
110 w/ 5% > 130 w/ 5%              (P = 0.005) 
4 
110 w/ 10% > 130 w/ 10%            (P < 0.001) 
110 w/ 10% > 130 w/ 5%             (P < 0.001) 
110 w/ 10% > 120 w/ 2.5%           (P < 0.001) 
14 
110 w/ 10% > 130 w/ 10%            (P < 0.001) 
110 w/ 10% > 130 w/ 5%             (P < 0.001) 
110 w/ 10% > 130 w/ 2.5%           (P = 0.004) 
110 w/ 2.5% > 130 w/ 10%           (P = 0.003) 
110 w/ 2.5% > 130 w/ 5%            (P = 0.005) 
110 w/ 5% > 130 w/ 10%             (P = 0.005) 
110 w/ 5% > 130 w/ 5%              (P = 0.007) 
24 
110 w/ 10% > 130 w/ 10%            (P < 0.001) 
110 w/ 10% > 130 w/ 5%             (P = 0.002) 
110 w/ 10% > 130 w/ 2.5%           (P = 0.011) 
110 w/ 5% > 130 w/ 10%             (P < 0.001) 
110 w/ 5% > 130 w/ 5%              (P = 0.004) 
110 w/ 5% > 130 w/ 2.5%            (P = 0.016) 
110 w/ 2.5% > 130 w/ 10%           (P = 0.001) 
110 w/ 2.5% > 130 w/ 5%            (P = 0.019) 
48 
110 w/ 10% > 130 w/ 10%            (P < 0.001) 
110 w/ 10% > 130 w/ 5%             (P = 0.002) 
110 w/ 10% > 130 w/ 2.5%           (P = 0.049) 
110 w/ 5% > 130 w/ 10%             (P < 0.001) 
110 w/ 5% > 130 w/ 5%              (P = 0.001) 
110 w/ 5% > 130 w/ 2.5%            (P = 0.028) 
110 w/ 2.5% > 130 w/ 10%           (P < 0.001) 
110 w/ 2.5% > 130 w/ 5%            (P = 0.003) 
120 w/ 5% > 130 w/ 10%             (P = 0.042) 
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120 w/ 2.5% > 130 w/ 10%           (P = 0.042) 
72 
110 w/ 10% > 130 w/ 10%            (P = 0.006) 
110 w/ 10% > 130 w/ 5%             (P = 0.031) 
110 w/ 5% > 130 w/ 10%             (P = 0.010) 
120 
110 w/ 10% > 130 w/ 10%            (P < 0.001) 
110 w/ 10% > 130 w/ 5%             (P < 0.001) 
110 w/ 10% > 130 w/ 2.5%           (P = 0.015) 
110 w/ 5% > 130 w/ 10%             (P < 0.001) 
110 w/ 5% > 130 w/ 5%              (P < 0.001) 
110 w/ 5% > 130 w/ 2.5%            (P = 0.017) 
110 w/ 2.5% > 130 w/ 10%           (P = 0.003) 
110 w/ 2.5% > 130 w/ 5%            (P = 0.007) 
168 
110 w/ 5% > 130 w/ 10%             (P < 0.001) 
110 w/ 5% > 130 w/ 5%              (P < 0.001) 
110 w/ 5% > 130 w/ 2.5%            (P < 0.001) 
110 w/ 5% > 120 w/ 10%             (P = 0.017) 
110 w/ 5% > 120 w/ 5%              (P = 0.004) 
110 w/ 5% > 120 w/ 2.5%            (P = 0.013) 
110 w/ 10% > 130 w/ 10%            (P < 0.001) 
110 w/ 10% > 130 w/ 5%             (P < 0.001) 
110 w/ 10% > 130 w/ 2.5%           (P = 0.004) 
110 w/ 10% > 120 w/ 5%             (P = 0.038) 
110 w/ 2.5% > 130 w/ 5%            (P = 0.004) 
110 w/ 2.5% > 130 w/ 10%           (P = 0.010) 
 
   
Table 19 : Pairwise differences at times for long term release 
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Time 
(min) 1 2 4 8 16 32 64 128 
1   XX No 0.039 <0.001 <0.001 <0.001 <0.001 <0.001
2    XX No <0.001 <0.001 <0.001 <0.001 <0.001
4     XX <0.001 <0.001 <0.001 <0.001 <0.001
8      XX No <0.001 <0.001 <0.001
16      XX No 0.045 <0.001
32       XX No No 
64        XX No 
128         XX 
 
Table 20 : P-values for Tukey’s W for pairwise comparison of 
concentrations over time for 110 mg/ml with 2.5% tetracycline 
 
 
Time 
(min) 1 2 4 8 16 32 64 128 
1   XX No <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
2    XX 0.004 <0.001 <0.001 <0.001 <0.001 <0.001
4     XX <0.001 <0.001 <0.001 <0.001 <0.001
8      XX No 0.018 <0.001 <0.001
16      XX No <0.001 <0.001
32       XX No <0.001
64        XX 0.042 
128         XX 
 
Table 21 : P-values for Tukey’s W for pairwise comparison of 
concentrations over time for 110 mg/ml with 5% tetracycline 
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Time 
(min) 1 2 4 8 16 32 64 128 
1   XX No <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
2    XX <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
4     XX 0.001 <0.001 <0.001 <0.001 <0.001
8      XX 0.02 <0.001 <0.001 <0.001
16      XX No <0.001 <0.001
32       XX 0.042 0.025 
64        XX No 
128         XX 
 
Table 22 : P-values for Tukey’s W for pairwise comparison of 
concentrations over time for 110 mg/ml with 10% tetracycline  
 
Time 
(min) 1 2 4 8 16 32 64 128 
1  XX No 0.039 <0.001 <0.001 <0.001 <0.001 <0.001
2   XX No <0.001 <0.001 <0.001 <0.001 <0.001
4    XX <0.001 <0.001 <0.001 <0.001 <0.001
8     XX No <0.001 <0.001 <0.001
16      XX No 0.045 <0.001
32       XX No No 
64        XX No 
128         XX 
 
 
 
Table 23 : P-values for Tukey’s W for pairwise comparison of 
concentrations over time for 120 mg/ml with 2.5% tetracycline 
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Time 
(min) 1 2 4 8 16 32 64 128 
1  XX No <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
2   XX 0.004 <0.001 <0.001 <0.001 <0.001 <0.001
4    XX <0.001 <0.001 <0.001 <0.001 <0.001
8     XX No 0.018 <0.001 <0.001
16      XX No No <0.001
32       XX No <0.001
64        XX 0.042 
128         XX 
 
 
Table 24 : P-values for Tukey’s W for pairwise comparison of 
concentrations over time for 120 mg/ml with 5% tetracycline 
 
 
 
Time 
(min) 1 2 4 8 16 32 64 128 
1  XX <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
2   XX <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
4    XX 0.001 <0.001 <0.001 <0.001 <0.001
8     XX 0.02 <0.001 <0.001 <0.001
16      XX No <0.001 <0.001
32       XX 0.042 0.025 
64        XX No 
128         XX 
 
 
Table 25 : P-values for Tukey’s W for pairwise comparison of 
concentrations over time for 120 mg/ml with 10% tetracycline  
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Time 
(min) 1 2 4 8 16 32 64 128 
1  XX No No <0.001 <0.001 <0.001 <0.001 <0.001
2   XX No 0.001 <0.001 <0.001 <0.001 <0.001
4    XX No <0.001 <0.001 <0.001 <0.001
8     XX No <0.001 <0.001 <0.001
16      XX 0.010 <0.001 <0.001
32       XX No 0.003 
64        XX No 
128         XX 
 
 
Table 26 : P-values for Tukey’s W for pairwise comparison of 
concentrations over time for 130 mg/ml with 2.5% tetracycline 
 
Time 
(min) 1 2 4 8 16 32 64 128 
1  XX 0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
2   XX 0.002 <0.001 <0.001 <0.001 <0.001 <0.001
4    XX No <0.001 <0.001 <0.001 <0.001
8     XX 0.015 <0.001 <0.001 <0.001
16      XX No 0.015 <0.001
32       XX No 0.01 
64        XX No 
128         XX 
 
 
Table 27 : P-values for Tukey’s W for pairwise comparison of 
concentrations over time for 130 mg/ml with 5% tetracycline 
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Time 
(min) 1 2 4 8 16 32 64 128 
1  XX <0.001 0.039 <0.001 <0.001 <0.001 <0.001 <0.001
2   XX 0.004 <0.001 <0.001 <0.001 <0.001 <0.001
4    XX No <0.001 <0.001 <0.001 <0.001
8     XX <0.001 <0.001 <0.001 <0.001
16      XX 0.018 <0.001 <0.001
32       XX No 0.002 
64        XX No 
128         XX 
 
 
Table 28 : P-values for Tukey’s W for pairwise comparison of 
concentrations over time for 130 mg/ml with 10% tetracycline  
 
 
Time 
(hr) 
1 
hr 
4   
hr 
14  
hr 
24  
hr 
48  
hr 
72  
hr 
120 
hr 
168  
hr 
1 hr XX No No 0.006 0.004 0.006 0.001 <0.001
4 hr  XX No No No No No No 
14 hr   XX No No No No No 
24 hr    XX No No No No 
48 hr     XX No No No 
72 hr      XX No No 
120 hr       XX No 
168 hr        XX 
 
Table 29 : P-values for Tukey’s W for pairwise comparison of 
concentrations over time for 110 mg/ml with 5% tetracycline 
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Time 
(hr) 
1 
hr 
4   
hr 
14  
hr 
24  
hr 
48  
hr 
72  
hr 
120 
hr 
168 
hr 
1 hr XX No No No 0.009 No No No 
4 hr  XX No No No No No No 
14 hr   XX No No No No No 
24 hr    XX No No No No 
48 hr     XX No No No 
72 hr      XX No No 
120 hr       XX No 
168 hr        XX 
 
Table 30 : P-values for Tukey’s W for pairwise comparison of 
concentrations over time for 120 mg/ml with 5% tetracycline 
 
Time 
(hr) 
1 
hr 
4   
hr 
14  
hr 
24  
hr 
48  
hr 
72  
hr 
120 
hr 
168 
hr 
1 hr XX No No 0.013 0.031 0.027 0.048 No 
4 hr  XX No No No No No No 
14 hr   XX No No No No No 
24 hr    XX No No No No 
48 hr     XX No No No 
72 hr      XX No No 
120 hr       XX No 
168 hr        XX 
 
Table 31 : P-values for Tukey’s W for pairwise comparison of 
concentrations over time for 130 mg/ml with 5% tetracycline 
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